BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500-503. [PMID: 21460848 DOI: 10.1038/nm.2344] [Cited by in Crossref: 885] [Cited by in F6Publishing: 706] [Article Influence: 88.5] [Reference Citation Analysis]
Number Citing Articles
1 Patra KC, Bardeesy N, Mizukami Y. Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. Clin Transl Gastroenterol. 2017;8:e86. [PMID: 28383565 DOI: 10.1038/ctg.2017.3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
2 Chang VH, Chu PY, Peng SL, Mao TL, Shan YS, Hsu CF, Lin CY, Tsai KK, Yu WC, Ch’ang HJ. Krüppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma. Am J Pathol. 2012;181:423-430. [PMID: 22688058 DOI: 10.1016/j.ajpath.2012.04.025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
3 Ehlen L, Arndt J, Treue D, Bischoff P, Loch FN, Hahn EM, Kotsch K, Klauschen F, Beyer K, Margonis GA, Kreis ME, Kamphues C. Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. BMC Cancer. 2020;20:417. [PMID: 32404074 DOI: 10.1186/s12885-020-06929-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
4 Bertucci F, Birnbaum DJ, Finetti P, Gilabert M, Poizat F, Raoul JL, Birnbaum D, Mamessier E. Prognostic Value of Molecular Subtypes in Pancreatic Cancer. Pancreas 2017;46:e29-31. [PMID: 28291163 DOI: 10.1097/MPA.0000000000000787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
5 Krepline A, Tsai S. Has Personalized Medicine for Pancreatic Cancer Arrived? Advances in Surgery 2019;53:103-15. [DOI: 10.1016/j.yasu.2019.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Fakhri B, Lim KH. Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. J Gastrointest Oncol. 2017;8:379-386. [PMID: 28736626 DOI: 10.21037/jgo.2016.11.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
7 Willenbrock F, Cox CM, Parkes EE, Wilhelm-Benartzi CS, Abraham AG, Owens R, Sabbagh A, Jones CM, Hughes DLI, Maughan T, Hurt CN, O'Neill EE, Mukherjee S. Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. Br J Cancer 2021;124:581-6. [PMID: 33100327 DOI: 10.1038/s41416-020-01120-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, Fenoglio S, Luengo A, Lees JA, Vander Heiden MG, Lauffenburger DA, Hemann MT. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Cancer Res 2019;79:5723-33. [PMID: 31484670 DOI: 10.1158/0008-5472.CAN-19-0960] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 16.5] [Reference Citation Analysis]
9 Froeling F, Tuveson D. Pancreatic cancer foiled by a switch of tumour subtype. Nature 2018;557:500-1. [PMID: 29777189 DOI: 10.1038/d41586-018-05129-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
10 Zhang P, Xia Q, Liu L, Li S, Dong L. Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy. Front Mol Biosci 2020;7:562798. [PMID: 33102518 DOI: 10.3389/fmolb.2020.562798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
11 Aguirre AJ. Refining Classification of Pancreatic Cancer Subtypes to Improve Clinical Care. Gastroenterology 2018;155:1689-91. [PMID: 30419209 DOI: 10.1053/j.gastro.2018.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65. [PMID: 28365159 DOI: 10.1016/j.eururo.2017.03.010] [Cited by in Crossref: 124] [Cited by in F6Publishing: 95] [Article Influence: 31.0] [Reference Citation Analysis]
13 Benitz S, Straub T, Mahajan UM, Mutter J, Czemmel S, Unruh T, Wingerath B, Deubler S, Fahr L, Cheng T, Nahnsen S, Bruns P, Kong B, Raulefs S, Ceyhan GO, Mayerle J, Steiger K, Esposito I, Kleeff J, Michalski CW, Regel I. Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis. Gut 2019;68:2007-18. [DOI: 10.1136/gutjnl-2018-317208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
14 Liu X, Gündel B, Li X, Liu J, Wright A, Löhr M, Arvidsson G, Heuchel R. 3D heterospecies spheroids of pancreatic stroma and cancer cells demonstrate key phenotypes of pancreatic ductal adenocarcinoma. Transl Oncol 2021;14:101107. [PMID: 33946033 DOI: 10.1016/j.tranon.2021.101107] [Reference Citation Analysis]
15 Mesmar F, Dai B, Ibrahim A, Hases L, Jafferali MH, Jose Augustine J, DiLorenzo S, Kang Y, Zhao Y, Wang J, Kim M, Lin CY, Berkenstam A, Fleming J, Williams C. Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling. Cancer Med 2019;8:7705-19. [PMID: 31568691 DOI: 10.1002/cam4.2581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ. CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. Cell Rep 2018;23:1448-60. [PMID: 29719257 DOI: 10.1016/j.celrep.2018.03.131] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 41.0] [Reference Citation Analysis]
17 Iovanna J, Dusetti N. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road. Cancer Lett 2017;410:63-7. [PMID: 28947138 DOI: 10.1016/j.canlet.2017.09.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
18 Zhou Q, Bauden M, Andersson R, Hu D, Marko-Varga G, Xu J, Sasor A, Dai H, Pawłowski K, Said Hilmersson K, Chen X, Ansari D. YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling. J Transl Med 2020;18:77. [PMID: 32054505 DOI: 10.1186/s12967-020-02254-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
19 González-Borja I, Viúdez A, Goñi S, Santamaria E, Carrasco-García E, Pérez-Sanz J, Hernández-García I, Sala-Elarre P, Arrazubi V, Oyaga-Iriarte E, Zárate R, Arévalo S, Sayar O, Vera R, Fernández-Irigoyen J. Omics Approaches in Pancreatic Adenocarcinoma. Cancers (Basel) 2019;11:E1052. [PMID: 31349663 DOI: 10.3390/cancers11081052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Krah NM, De La O JP, Swift GH, Hoang CQ, Willet SG, Chen Pan F, Cash GM, Bronner MP, Wright CV, MacDonald RJ. The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma. Elife. 2015;4. [PMID: 26151762 DOI: 10.7554/elife.07125] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 12.7] [Reference Citation Analysis]
21 Anaya DA, Dogra P, Wang Z, Haider M, Ehab J, Jeong DK, Ghayouri M, Lauwers GY, Thomas K, Kim R, Butner JD, Nizzero S, Ramírez JR, Plodinec M, Sidman RL, Cavenee WK, Pasqualini R, Arap W, Fleming JB, Cristini V. A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases. Cancers (Basel) 2021;13:444. [PMID: 33503971 DOI: 10.3390/cancers13030444] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Drifka CR, Loeffler AG, Mathewson K, Keikhosravi A, Eickhoff JC, Liu Y, Weber SM, Kao WJ, Eliceiri KW. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget 2016;7:76197-213. [PMID: 27776346 DOI: 10.18632/oncotarget.12772] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 27.7] [Reference Citation Analysis]
23 Dreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki EM, Dray E, Serrels B, Caligiuri G, Rebus S, Plenker D, Galluzzo Z, Brunton H, Cunningham R, Tesson M, Nourse C, Bailey UM, Jones M, Moran-Jones K, Wright DW, Duthie F, Oien K, Evers L, McKay CJ, McGregor GA, Gulati A, Brough R, Bajrami I, Pettitt S, Dziubinski ML, Candido J, Balkwill F, Barry ST, Grützmann R, Rahib L, Johns A, Pajic M, Froeling FEM, Beer P, Musgrove EA, Petersen GM, Ashworth A, Frame MC, Crawford HC, Simeone DM, Lord C, Mukhopadhyay D, Pilarsky C, Tuveson DA, Cooke SL, Jamieson NB, Morton JP, Sansom OJ, Bailey PJ, Biankin AV, Chang DK; Glasgow Precision Oncology Laboratory,., Australian Pancreatic Cancer Genome Initiative. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology 2021;160:362-377.e13. [PMID: 33039466 DOI: 10.1053/j.gastro.2020.09.043] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
24 Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 2015;16:43-51. [PMID: 25485960 DOI: 10.4161/15384047.2014.986967] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
25 Permuth JB, Dezsi KB, Vyas S, Ali KN, Basinski TL, Utuama OA, Denbo JW, Klapman J, Dam A, Carballido E, Kim DW, Pimiento JM, Powers BD, Otto AK, Choi JW, Chen DT, Teer JK, Beato F, Ward A, Cortizas EM, Whisner SY, Williams IE, Riner AN, Tardif K, Velanovich V, Karachristos A, Douglas WG, Legaspi A, Allan BJ, Meredith K, Molina-Vega MA, Bao P, St Julien J, Huguet KL, Green L, Odedina FT, Kumar NB, Simmons VN, George TJ, Vadaparampil ST, Hodul PJ, Arnoletti JP, Awad ZT, Bose D, Jiang K, Centeno BA, Gwede CK, Malafa M, Judge SM, Judge AR, Jeong D, Bloomston M, Merchant NB, Fleming JB, Trevino JG, On Behalf Of The Florida Pancreas Collaborative. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. Cancers (Basel) 2021;13:809. [PMID: 33671939 DOI: 10.3390/cancers13040809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Eyres M, Lanfredini S, Xu H, Burns A, Blake A, Willenbrock F, Goldin R, Hughes D, Hughes S, Thapa A, Vavoulis D, Hubert A, D'Costa Z, Sabbagh A, Abraham AG, Blancher C, Jones S, Verrill C, Silva M, Soonawalla Z, Maughan T, Schuh A, Mukherjee S, O'Neill E. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. Gastroenterology 2021;161:653-668.e16. [PMID: 33915173 DOI: 10.1053/j.gastro.2021.04.044] [Reference Citation Analysis]
27 Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, Wohl D, Steinmann A, Stark R, Drury A, Walters SN, Vennin C, Burgess A, Pinese M, Chantrill LA, Cowley MJ, Molloy TJ, Waddell N, Johns A, Grimmond SM, Chang DK, Biankin AV, Sansom OJ, Morton JP, Grey ST, Cox TR, Turchini J, Samra J, Clarke SJ, Timpson P, Gill AJ, Pajic M; Australian Pancreatic Cancer Genome Initiative (APGI). Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut 2018;67:2142-55. [PMID: 29080858 DOI: 10.1136/gutjnl-2017-315144] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 15.3] [Reference Citation Analysis]
28 Herbst B, Zheng L. Precision medicine in pancreatic cancer: treating every patient as an exception. The Lancet Gastroenterology & Hepatology 2019;4:805-10. [DOI: 10.1016/s2468-1253(19)30175-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
29 Karnovsky A, Weymouth T, Hull T, Tarcea VG, Scardoni G, Laudanna C, Sartor MA, Stringer KA, Jagadish HV, Burant C. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics. 2012;28:373-380. [PMID: 22135418 DOI: 10.1093/bioinformatics/btr661] [Cited by in Crossref: 251] [Cited by in F6Publishing: 212] [Article Influence: 25.1] [Reference Citation Analysis]
30 Kaissis G, Braren R. Pancreatic cancer detection and characterization-state of the art cross-sectional imaging and imaging data analysis. Transl Gastroenterol Hepatol 2019;4:35. [PMID: 31231702 DOI: 10.21037/tgh.2019.05.04] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
31 Barcellini A, Peloso A, Pugliese L, Vitolo V, Cobianchi L. Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress. Onco Targets Ther 2020;13:12705-20. [PMID: 33335406 DOI: 10.2147/OTT.S220971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Mello SS, Valente LJ, Raj N, Seoane JA, Flowers BM, McClendon J, Bieging-Rolett KT, Lee J, Ivanochko D, Kozak MM, Chang DT, Longacre TA, Koong AC, Arrowsmith CH, Kim SK, Vogel H, Wood LD, Hruban RH, Curtis C, Attardi LD. A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Cancer Cell. 2017;32:460-473.e6. [PMID: 29017057 DOI: 10.1016/j.ccell.2017.09.007] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 19.8] [Reference Citation Analysis]
33 Carstens JL, Yang S, Correa de Sampaio P, Zheng X, Barua S, McAndrews KM, Rao A, Burks JK, Rhim AD, Kalluri R. Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer. Cell Rep 2021;35:108990. [PMID: 33852841 DOI: 10.1016/j.celrep.2021.108990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ferreira RMM, Sancho R, Messal HA, Nye E, Spencer-Dene B, Stone RK, Stamp G, Rosewell I, Quaglia A, Behrens A. Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression. Cell Rep 2017;21:966-78. [PMID: 29069604 DOI: 10.1016/j.celrep.2017.09.093] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
35 Flowers BM, Xu H, Mulligan AS, Hanson KJ, Seoane JA, Vogel H, Curtis C, Wood LD, Attardi LD. Cell of Origin Influences Pancreatic Cancer Subtype. Cancer Discov 2021;11:660-77. [PMID: 34009137 DOI: 10.1158/2159-8290.CD-20-0633] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Garay JP, Gray JW. Omics and therapy - a basis for precision medicine. Mol Oncol 2012;6:128-39. [PMID: 22445068 DOI: 10.1016/j.molonc.2012.02.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
37 Antonova DV, Zinovyeva MV, Kondratyeva LG, Sass AV, Alekseenko IV, Pleshkan VV. Possibility for Transcriptional Targeting of Cancer-Associated Fibroblasts—Limitations and Opportunities. IJMS 2021;22:3298. [DOI: 10.3390/ijms22073298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Zhang Z, Gu J, Yin M, Wang D, Ma C, Du J, Lin Z, Hu S, Wang X, Li Y, Tan G, Luo H, Wei G. Establishment and Investigation of a Multiple Gene Expression Signature to Predict Long-Term Survival in Pancreatic Cancer. Biomed Res Int 2020;2020:1570862. [PMID: 33015155 DOI: 10.1155/2020/1570862] [Reference Citation Analysis]
39 Zhao L, Liu B. Identification of potential prognostic ceRNA module biomarkers in patients with pancreatic adenocarcinoma. Oncotarget 2017;8:94493-504. [PMID: 29212244 DOI: 10.18632/oncotarget.21783] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
40 Porta M, Pumarega J, Amaral AFS, Genkinger JM, Camargo J, Mucci L, Alguacil J, Gasull M, Zhang X, Morales E, Iglesias M, Ogino S, Engel LS; PANKRAS II Study Group. Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma. Environ Res 2020;190:109781. [PMID: 32791343 DOI: 10.1016/j.envres.2020.109781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Nagrath S, Jack RM, Sahai V, Simeone DM. Opportunities and Challenges for Pancreatic Circulating Tumor Cells. Gastroenterology. 2016;151:412-426. [PMID: 27339829 DOI: 10.1053/j.gastro.2016.05.052] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
42 Torres C, Grippo PJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med 2018;50:277-87. [PMID: 29537309 DOI: 10.1080/07853890.2018.1453168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
43 Camelo F, Le A. The Intricate Metabolism of Pancreatic Cancers. Adv Exp Med Biol 2021;1311:77-88. [PMID: 34014535 DOI: 10.1007/978-3-030-65768-0_5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Gough NR, Xiang X, Mishra L. TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer. Gastroenterology 2021;161:434-452.e15. [PMID: 33940008 DOI: 10.1053/j.gastro.2021.04.064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Rademaker G, Hennequière V, Brohée L, Nokin MJ, Lovinfosse P, Durieux F, Gofflot S, Bellier J, Costanza B, Herfs M, Peiffer R, Bettendorff L, Deroanne C, Thiry M, Delvenne P, Hustinx R, Bellahcène A, Castronovo V, Peulen O. Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness. Oncogene 2018;37:4398-412. [PMID: 29720728 DOI: 10.1038/s41388-018-0287-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
46 Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Müller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut 2020;69:1472-82. [PMID: 32001555 DOI: 10.1136/gutjnl-2018-317856] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 22.0] [Reference Citation Analysis]
47 Aulas A, Finetti P, Lyons SM, Bertucci F, Birnbaum D, Acquaviva C, Mamessier E. Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins? Cancers (Basel) 2020;12:E2470. [PMID: 32882814 DOI: 10.3390/cancers12092470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
48 Slapak EJ, Kong L, El Mandili M, Nieuwland R, Kros A, Bijlsma MF, Spek CA. ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Cancers (Basel) 2021;13:3321. [PMID: 34282781 DOI: 10.3390/cancers13133321] [Reference Citation Analysis]
49 Keleg S, Titov A, Heller A, Giese T, Tjaden C, Ahmad SS, Gaida MM, Bauer AS, Werner J, Giese NA. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors. PLoS One 2014;9:e100178. [PMID: 24932730 DOI: 10.1371/journal.pone.0100178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
50 Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med. 2014;3:572-579. [PMID: 24574334 DOI: 10.1002/cam4.208] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
51 Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression. Gastroenterology. 2013;145:1110-1120. [PMID: 23896173 DOI: 10.1053/j.gastro.2013.07.040] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 6.4] [Reference Citation Analysis]
52 Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut 2021;70:606-17. [PMID: 32855305 DOI: 10.1136/gutjnl-2019-319984] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 20.0] [Reference Citation Analysis]
53 Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2012;2:685-93. [PMID: 22628411 DOI: 10.1158/2159-8290.CD-11-0347] [Cited by in Crossref: 188] [Cited by in F6Publishing: 114] [Article Influence: 20.9] [Reference Citation Analysis]
54 Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. [PMID: 26185420 DOI: 10.2147/DDDT.S60328] [Cited by in Crossref: 74] [Cited by in F6Publishing: 44] [Article Influence: 12.3] [Reference Citation Analysis]
55 Escobar-Hoyos LF, Penson A, Kannan R, Cho H, Pan CH, Singh RK, Apken LH, Hobbs GA, Luo R, Lecomte N, Babu S, Pan FC, Alonso-Curbelo D, Morris JP 4th, Askan G, Grbovic-Huezo O, Ogrodowski P, Bermeo J, Saglimbeni J, Cruz CD, Ho YJ, Lawrence SA, Melchor JP, Goda GA, Bai K, Pastore A, Hogg SJ, Raghavan S, Bailey P, Chang DK, Biankin A, Shroyer KR, Wolpin BM, Aguirre AJ, Ventura A, Taylor B, Der CJ, Dominguez D, Kümmel D, Oeckinghaus A, Lowe SW, Bradley RK, Abdel-Wahab O, Leach SD. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell 2020;38:198-211.e8. [PMID: 32559497 DOI: 10.1016/j.ccell.2020.05.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
56 Lai SW, Bamodu OA, Chen JH, Wu AT, Lee WH, Chao TY, Yeh CT. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. Cells 2020;9:E911. [PMID: 32276472 DOI: 10.3390/cells9040911] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Nicosia L, Alongi F, Andreani S, Ruggieri R, Rusev B, Mantoan B, Lawlor RT, Pea A, Scarpa A, Agolli L, Corbo V, D'Agosto S. Combinatorial Effect of Magnetic Field and Radiotherapy in PDAC Organoids: A Pilot Study. Biomedicines 2020;8:E609. [PMID: 33327494 DOI: 10.3390/biomedicines8120609] [Reference Citation Analysis]
58 Feng Z, Li K, Lou J, Wu Y, Peng C. An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. Front Cell Dev Biol 2021;9:665161. [PMID: 33996821 DOI: 10.3389/fcell.2021.665161] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Jonckheere N, Auwercx J, Hadj Bachir E, Coppin L, Boukrout N, Vincent A, Neve B, Gautier M, Treviño V, Van Seuningen I. Unsupervised Hierarchical Clustering of Pancreatic Adenocarcinoma Dataset from TCGA Defines a Mucin Expression Profile that Impacts Overall Survival. Cancers (Basel) 2020;12:E3309. [PMID: 33182511 DOI: 10.3390/cancers12113309] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
60 Hayashi A, Hong J, Iacobuzio-Donahue CA. The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol 2021;18:469-81. [PMID: 34089011 DOI: 10.1038/s41575-021-00463-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
61 Bulle A, Dekervel J, Deschuttere L, Nittner D, Libbrecht L, Janky R, Plaisance S, Topal B, Coosemans A, Lambrechts D, Van Cutsem E, Verslype C, van Pelt J. Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. Transl Oncol 2020;13:100743. [PMID: 32145636 DOI: 10.1016/j.tranon.2020.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
62 Szadvari I, Krizanova O, Babula P. Athymic nude mice as an experimental model for cancer treatment. Physiol Res 2016;65:S441-53. [PMID: 28006926 DOI: 10.33549/physiolres.933526] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
63 Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MHA, Bavi P, Bartlett JMS, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol 2017;3:774-83. [PMID: 27768182 DOI: 10.1001/jamaoncol.2016.3916] [Cited by in Crossref: 137] [Cited by in F6Publishing: 104] [Article Influence: 34.3] [Reference Citation Analysis]
64 Milan M, Balestrieri C, Alfarano G, Polletti S, Prosperini E, Nicoli P, Spaggiari P, Zerbi A, Cirulli V, Diaferia GR, Natoli G. Pancreatic Cancer Cells Require the Transcription Factor MYRF to Maintain ER Homeostasis. Dev Cell 2020;55:398-412.e7. [PMID: 32997974 DOI: 10.1016/j.devcel.2020.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
65 Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015;33:1779-1786. [PMID: 25918299 DOI: 10.1200/jco.2014.59.7625] [Cited by in Crossref: 49] [Cited by in F6Publishing: 29] [Article Influence: 8.2] [Reference Citation Analysis]
66 Grimont A, Pinho AV, Cowley MJ, Augereau C, Mawson A, Giry-Laterrière M, Van den Steen G, Waddell N, Pajic M, Sempoux C, Wu J, Grimmond SM, Biankin AV, Lemaigre FP, Rooman I, Jacquemin P. SOX9 regulates ERBB signalling in pancreatic cancer development. Gut 2015;64:1790-9. [PMID: 25336113 DOI: 10.1136/gutjnl-2014-307075] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
67 Gerrard DL, Boyd JR, Stein GS, Jin VX, Frietze S. Disruption of Broad Epigenetic Domains in PDAC Cells by HAT Inhibitors. Epigenomes 2019;3:11. [PMID: 31815011 DOI: 10.3390/epigenomes3020011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
68 Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16:553-565. [PMID: 27444064 DOI: 10.1038/nrc.2016.66] [Cited by in Crossref: 183] [Cited by in F6Publishing: 159] [Article Influence: 36.6] [Reference Citation Analysis]
69 Gómez-Tomás Á, Pumarega J, Alguacil J, Amaral AFS, Malats N, Pallarès N, Gasull M, Porta M; PANKRAS II Study Group. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma. Environ Mol Mutagen 2019;60:693-703. [PMID: 31066938 DOI: 10.1002/em.22296] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
70 Bijlsma MF, Sadanandam A, Tan P, Vermeulen L. Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2017;14:333-42. [PMID: 28400627 DOI: 10.1038/nrgastro.2017.33] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
71 [DOI: 10.1101/2020.08.25.267336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Anderson M, Marayati R, Moffitt R, Yeh JJ. Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget 2017;8:56081-94. [PMID: 28915575 DOI: 10.18632/oncotarget.9760] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 16.4] [Reference Citation Analysis]
73 Kalloger SE, Karasinska JM, Keung MS, Thompson DL, Ho J, Chow C, Gao D, Topham JT, Warren C, Wong HL, Lee MK, Renouf DJ, Schaeffer DF. Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. Int J Cancer 2021;148:481-91. [PMID: 32955725 DOI: 10.1002/ijc.33304] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 2019;9:1102-1123. [PMID: 31197017 DOI: 10.1158/2159-8290.cd-19-0094] [Cited by in Crossref: 308] [Cited by in F6Publishing: 185] [Article Influence: 154.0] [Reference Citation Analysis]
75 Cui Y, Brosnan JA, Blackford AL, Sur S, Hruban RH, Kinzler KW, Vogelstein B, Maitra A, Diaz LA Jr, Iacobuzio-Donahue CA, Eshleman JR. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res 2012;18:6519-30. [PMID: 22753594 DOI: 10.1158/1078-0432.CCR-12-0827] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
76 Schaafsma E, Yuan Y, Zhao Y, Cheng C. Computational STAT3 activity inference reveals its roles in the pancreatic tumor microenvironment. Sci Rep 2019;9:18257. [PMID: 31796877 DOI: 10.1038/s41598-019-54791-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
77 Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers (Basel). 2019;11. [PMID: 30965637 DOI: 10.3390/cancers11040497] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
78 Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surg Oncol Clin N Am 2017;26:431-53. [PMID: 28576181 DOI: 10.1016/j.soc.2017.01.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
79 Hussain Z, Nigri J, Tomasini R. The Cellular and Biological Impact of Extracellular Vesicles in Pancreatic Cancer. Cancers (Basel) 2021;13:3040. [PMID: 34207163 DOI: 10.3390/cancers13123040] [Reference Citation Analysis]
80 Ko AH. Raising the bar for the adjuvant treatment of pancreatic cancer. The Lancet 2016;388:214-5. [DOI: 10.1016/s0140-6736(16)30680-8] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Siveke JT. The increasing diversity of KRAS signaling in pancreatic cancer. Gastroenterology 2014;147:736-9. [PMID: 25167989 DOI: 10.1053/j.gastro.2014.08.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
82 Teo M, Crotty GF, O'Súilleabháin C, Ridgway PF, Conlon KC, Power DG, McDermott RS. Identification of distinct phenotypes of locally advanced pancreatic adenocarcinoma. J Gastrointest Cancer 2013;44:73-8. [PMID: 22829058 DOI: 10.1007/s12029-012-9419-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Law HC, Lagundžin D, Clement EJ, Qiao F, Wagner ZS, Krieger KL, Costanzo-Garvey D, Caffrey TC, Grem JL, DiMaio DJ, Grandgenett PM, Cook LM, Fisher KW, Yu F, Hollingsworth MA, Woods NT. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Clin Cancer Res 2020;26:1065-76. [PMID: 31848187 DOI: 10.1158/1078-0432.CCR-19-1496] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
84 Heller A, Gaida MM, Männle D, Giese T, Scarpa A, Neoptolemos JP, Hackert T, Strobel O, Hoheisel JD, Giese NA, Bauer AS. Stratification of pancreatic tissue samples for molecular studies: RNA-based cellular annotation procedure. Pancreatology 2015;15:423-31. [PMID: 26118650 DOI: 10.1016/j.pan.2015.05.480] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
85 Neuzillet C, Rousseau B, Kocher H, Bourget P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. Pharmacol Ther. 2017;174:145-172. [PMID: 28223233 DOI: 10.1016/j.pharmthera.2017.02.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
86 Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, Ouellette MM, Jain M, Lin C, Batra SK. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2017;1868:69-92. [PMID: 28249796 DOI: 10.1016/j.bbcan.2017.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
87 Kim HR, Yim J, Yoo HB, Lee SE, Oh S, Jung S, Hwang CI, Shin DM, Kim T, Yoo KH, Kim YS, Lee HW, Roe JS. EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer. NAR Cancer 2021;3:zcab023. [PMID: 34316710 DOI: 10.1093/narcan/zcab023] [Reference Citation Analysis]
88 Grant TJ, Hua K, Singh A. Molecular Pathogenesis of Pancreatic Cancer. Prog Mol Biol Transl Sci. 2016;144:241-275. [PMID: 27865459 DOI: 10.1016/bs.pmbts.2016.09.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
89 Bazzichetto C, Conciatori F, Luchini C, Simionato F, Santoro R, Vaccaro V, Corbo V, Falcone I, Ferretti G, Cognetti F, Melisi D, Scarpa A, Ciuffreda L, Milella M. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. Cells 2020;9:E309. [PMID: 32012917 DOI: 10.3390/cells9020309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
90 Lee HS, Lee JS, Lee J, Kim EK, Kim H, Chung MJ, Park JY, Park SW, Song SY, Bang S. Establishment of pancreatic cancer cell lines with endoscopic ultrasound-guided biopsy via conditionally reprogrammed cell culture. Cancer Med 2019;8:3339-48. [PMID: 31044541 DOI: 10.1002/cam4.2210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
91 Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, Kong B, Fu DL, Bruns C, Zhao Y, Qin LX, Dong QZ. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther 2021;6:249. [PMID: 34219130 DOI: 10.1038/s41392-021-00659-4] [Reference Citation Analysis]
92 Moutinho-Ribeiro P, Macedo G, Melo SA. Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble? Front Endocrinol (Lausanne) 2018;9:779. [PMID: 30671023 DOI: 10.3389/fendo.2018.00779] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
93 Halperin DM, Varadhachary GR. Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter? Curr Oncol Rep 2014;16. [DOI: 10.1007/s11912-013-0366-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
94 Glaß M, Michl P, Hüttelmaier AS. RNA Binding Proteins as Drivers and Therapeutic Target Candidates in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2020;21:E4190. [PMID: 32545414 DOI: 10.3390/ijms21114190] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
95 Kim J, Jo YH, Jang M, Nguyen NNY, Yun HR, Ko SH, Shin Y, Lee JS, Kang I, Ha J, Choi TG, Kim SS. PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma. Cancers (Basel) 2019;11:E1749. [PMID: 31703415 DOI: 10.3390/cancers11111749] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
96 Wang Z, Qin J, Zhao J, Li J, Li D, Popp M, Popp F, Alakus H, Kong B, Dong Q, Nelson PJ, Zhao Y, Bruns CJ. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Theranostics 2020;10:7178-92. [PMID: 32641986 DOI: 10.7150/thno.43093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
97 Zhang S, Xue J, Zheng J, Wang S, Zhou J, Jiao Y, Geng Y, Wu J, Hannafon BN, Ding WQ. The superoxide dismutase 1 3'UTR maintains high expression of the SOD1 gene in cancer cells: The involvement of the RNA-binding protein AUF-1. Free Radic Biol Med 2015;85:33-44. [PMID: 25908445 DOI: 10.1016/j.freeradbiomed.2015.04.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
98 Hoare O, Fraunhoffer N, Elkaoutari A, Gayet O, Bigonnet M, Roques J, Nicolle R, McGuckin C, Forraz N, Sohier E, Tonon L, Wajda P, Boyault S, Attignon V, Tabone-Eglinger S, Barbier S, Mignard C, Duchamp O, Iovanna J, Dusetti NJ. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. Cancers (Basel) 2021;13:2473. [PMID: 34069519 DOI: 10.3390/cancers13102473] [Reference Citation Analysis]
99 Brouwer TP, Vahrmeijer AL, de Miranda NFCC. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cell Oncol (Dordr) 2021;44:261-78. [PMID: 33710604 DOI: 10.1007/s13402-021-00587-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Duconseil P, Gilabert M, Gayet O, Loncle C, Moutardier V, Turrini O, Calvo E, Ewald J, Giovannini M, Gasmi M, Bories E, Barthet M, Ouaissi M, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Viens P, Iovanna J, Dusetti N. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Am J Pathol 2015;185:1022-32. [PMID: 25765988 DOI: 10.1016/j.ajpath.2014.11.029] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
101 Luna J, Boni J, Cuatrecasas M, Bofill-De Ros X, Núñez-Manchón E, Gironella M, Vaquero EC, Arbones ML, de la Luna S, Fillat C. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut 2019;68:1465-76. [PMID: 30343272 DOI: 10.1136/gutjnl-2018-316128] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
102 Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol 2017;9:235-50. [PMID: 28656074 DOI: 10.4251/wjgo.v9.i6.235] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
103 Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L, Posner RG, Jones T, Han H, Sausen M, Velculescu VE, Drebin J, O'Dwyer P, Jameson G, Ramanathan RK, Von Hoff DD. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer 2017;117:572-82. [PMID: 28720843 DOI: 10.1038/bjc.2017.209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
104 Lin H, Xue X, Wang X, Dang S, Gu M. Application of artificial intelligence for the diagnosis, treatment, and prognosis of pancreatic cancer. AIG 2020;1:19-29. [DOI: 10.35712/aig.v1.i1.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Shenoy S. Cell plasticity in cancer: A complex interplay of genetic, epigenetic mechanisms and tumor micro-environment. Surg Oncol 2020;34:154-62. [PMID: 32891322 DOI: 10.1016/j.suronc.2020.04.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
106 Wan C, Gong C, Ji L, Liu X, Wang Y, Wang L, Shao M, Yang L, Fan S, Xiao Y, Wang X, Li M, Zhou G, Zhang Y. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma. Mol Cell Biochem 2015;410:25-35. [PMID: 26276310 DOI: 10.1007/s11010-015-2535-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
107 Hu D, Ansari D, Zhou Q, Sasor A, Said Hilmersson K, Andersson R. Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer. Scandinavian Journal of Gastroenterology 2019;54:246-51. [DOI: 10.1080/00365521.2019.1574360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
108 Jiang Y, Li Z, Zheng S, Chen H, Zhao X, Gao W, Bi Z, You K, Wang Y, Li W, Li L, Liu Y, Chen R. The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1. Tumor Biol 2016;37:3957-67. [DOI: 10.1007/s13277-015-4234-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
109 Tang ZC, Chu Y, Tan YY, Li J, Gao S. Pancreatic and duodenal homeobox-1 in pancreatic ductal adenocarcinoma and diabetes mellitus. Chin Med J (Engl) 2020;133:344-50. [PMID: 31904730 DOI: 10.1097/CM9.0000000000000628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
110 Porter RL, Magnus NKC, Thapar V, Morris R, Szabolcs A, Neyaz A, Kulkarni AS, Tai E, Chougule A, Hillis A, Golczer G, Guo H, Yamada T, Kurokawa T, Yashaswini C, Ligorio M, Vo KD, Nieman L, Liss AS, Deshpande V, Lawrence MS, Maheswaran S, Fernandez-Del Castillo C, Hong TS, Ryan DP, O'Dwyer PJ, Drebin JA, Ferrone CR, Haber DA, Ting DT. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2019:201914915. [PMID: 31843922 DOI: 10.1073/pnas.1914915116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
111 Mottini C, Cardone L. Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers. Int J Mol Sci 2020;21:E5023. [PMID: 32708716 DOI: 10.3390/ijms21145023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Qian X, Jiang C, Shen S, Zou X. GPRC5A: An emerging prognostic biomarker for predicting malignancy of Pancreatic Cancer based on bioinformatics analysis. J Cancer 2021;12:2010-22. [PMID: 33753999 DOI: 10.7150/jca.52578] [Reference Citation Analysis]
113 Barrett AS, Maller O, Pickup MW, Weaver VM, Hansen KC. Compartment resolved proteomics reveals a dynamic matrisome in a biomechanically driven model of pancreatic ductal adenocarcinoma. Journal of Immunology and Regenerative Medicine 2018;1:67-75. [DOI: 10.1016/j.regen.2018.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
114 Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Egeblad M, Park Y, Tuveson DA, Vakoc CR. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 2017;170:875-888.e20. [PMID: 28757253 DOI: 10.1016/j.cell.2017.07.007] [Cited by in Crossref: 182] [Cited by in F6Publishing: 147] [Article Influence: 45.5] [Reference Citation Analysis]
115 Ruess DA, Kayser C, Neubauer J, Fichtner-Feigl S, Hopt UT, Wittel UA. Carcinosarcoma of the Pancreas: Case Report With Comprehensive Literature Review. Pancreas. 2017;46:1225-1233. [PMID: 28902796 DOI: 10.1097/mpa.0000000000000904] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
116 Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, Link J, Pelz C, Heiser LM, Morton JP, Muthalagu N, Hoffman MT, Manning SL, Pratt ED, Kendsersky ND, Egbukichi N, Amery TS, Thoma MC, Jenny ZP, Rhim AD, Murphy DJ, Sansom OJ, Crawford HC, Sheppard BC, Sears RC. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nat Commun 2017;8:1728. [PMID: 29170413 DOI: 10.1038/s41467-017-01967-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
117 Liu L, Xu H, Wang W, Wu C, Chen Y, Yang J, Cen P, Xu J, Liu C, Long J. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer. 2015;136:2216-2227. [PMID: 25273947 DOI: 10.1002/ijc.29242] [Cited by in Crossref: 44] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
118 Rachakonda PS, Bauer AS, Xie H, Campa D, Rizzato C, Canzian F, Beghelli S, Greenhalf W, Costello E, Schanne M. Somatic mutations in exocrine pancreatic tumors: association with patient survival. PLoS One. 2013;8:e60870. [PMID: 23565280 DOI: 10.1371/journal.pone.0060870] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
119 Patel SH, Katz MHG, Ahmad SA. The Landmark Series: Preoperative Therapy for Pancreatic Cancer. Ann Surg Oncol 2021;28:4104-29. [PMID: 34047859 DOI: 10.1245/s10434-021-10075-1] [Reference Citation Analysis]
120 Sjoquist KM, Chin VT, Chantrill LA, O’Connor C, Hemmings C, Chang DK, Chou A, Pajic M, Johns AL, Nagrial AM. Personalising pancreas cancer treatment: When tissue is the issue. World J Gastroenterol. 2014;20:7849-7863. [PMID: 24976722 DOI: 10.3748/wjg.v20.i24.7849] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
121 Sasaki N, Gomi F, Hasegawa F, Hirano K, Fujiwara M, Toyoda M, Ishiwata T. Characterization of the metastatic potential of the floating cell component of MIA PaCa-2, a human pancreatic cancer cell line. Biochem Biophys Res Commun 2020;522:881-8. [PMID: 31806369 DOI: 10.1016/j.bbrc.2019.11.120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Barhli A, Cros J, Bartholin L, Neuzillet C. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. Dig Liver Dis 2018;50:979-90. [PMID: 30205952 DOI: 10.1016/j.dld.2018.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
123 Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016;22:61-68. [PMID: 26251290 DOI: 10.1158/1078-0432.ccr-15-0979] [Cited by in Crossref: 68] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
124 Chen CJ, Yang CJ, Yang SF, Huang MS, Liu YP. The MyoD family inhibitor domain-containing protein enhances the chemoresistance of cancer stem cells in the epithelial state by increasing β-catenin activity. Oncogene 2020;39:2377-90. [PMID: 31911618 DOI: 10.1038/s41388-019-1152-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Daman Z, Faghihi H, Montazeri H. Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer. Drug Dev Ind Pharm 2018;44:1434-42. [PMID: 29619850 DOI: 10.1080/03639045.2018.1459674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
126 Benzel J, Fendrich V. Familial Pancreatic Cancer. Oncol Res Treat. 2018;41:611-618. [PMID: 30269130 DOI: 10.1159/000493473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
127 Blasco MT, Navas C, Martín-Serrano G, Graña-Castro O, Lechuga CG, Martín-Díaz L, Djurec M, Li J, Morales-Cacho L, Esteban-Burgos L, Perales-Patón J, Bousquet-Mur E, Castellano E, Jacob HKC, Cabras L, Musteanu M, Drosten M, Ortega S, Mulero F, Sainz B Jr, Dusetti N, Iovanna J, Sánchez-Bueno F, Hidalgo M, Khiabanian H, Rabadán R, Al-Shahrour F, Guerra C, Barbacid M. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell 2019;35:573-587.e6. [PMID: 30975481 DOI: 10.1016/j.ccell.2019.03.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
128 Smith R, Liu M, Liby T, Bayani N, Bucher E, Chiotti K, Derrick D, Chauchereau A, Heiser L, Alumkal J, Feiler H, Carroll P, Korkola JE. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. Sci Rep 2020;10:21750. [PMID: 33303959 DOI: 10.1038/s41598-020-78798-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
129 Guan Y, Wang G, Fails D, Nagarajan P, Ge Y. Unraveling cancer lineage drivers in squamous cell carcinomas. Pharmacol Ther. 2020;206:107448. [PMID: 31836455 DOI: 10.1016/j.pharmthera.2019.107448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
130 Hermann PC, Trabulo SM, Sainz B Jr, Balic A, Garcia E, Hahn SA, Vandana M, Sahoo SK, Tunici P, Bakker A. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PLoS One. 2013;8:e66371. [PMID: 23825539 DOI: 10.1371/journal.pone.0066371] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
131 Klett H, Fuellgraf H, Levit-Zerdoun E, Hussung S, Kowar S, Küsters S, Bronsert P, Werner M, Wittel U, Fritsch R, Busch H, Boerries M. Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Front Genet 2018;9:108. [PMID: 29675033 DOI: 10.3389/fgene.2018.00108] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
132 Yuan S, Norgard RJ, Stanger BZ. Cellular Plasticity in Cancer. Cancer Discov 2019;9:837-51. [PMID: 30992279 DOI: 10.1158/2159-8290.CD-19-0015] [Cited by in Crossref: 104] [Cited by in F6Publishing: 47] [Article Influence: 52.0] [Reference Citation Analysis]
133 Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology 2019;156:2041-55. [PMID: 30660730 DOI: 10.1053/j.gastro.2018.12.039] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
134 Puleo F, Maréchal R, Demetter P, Bali MA, Calomme A, Closset J, Bachet JB, Deviere J, Van Laethem JL. New challenges in perioperative management of pancreatic cancer. World J Gastroenterol. 2015;21:2281-2293. [PMID: 25741134 DOI: 10.3748/wjg.v21.i8.2281] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
135 Shichi Y, Sasaki N, Michishita M, Hasegawa F, Matsuda Y, Arai T, Gomi F, Aida J, Takubo K, Toyoda M, Yoshimura H, Takahashi K, Ishiwata T. Enhanced morphological and functional differences of pancreatic cancer with epithelial or mesenchymal characteristics in 3D culture. Sci Rep 2019;9:10871. [PMID: 31350453 DOI: 10.1038/s41598-019-47416-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
136 Gabitova-Cornell L, Surumbayeva A, Peri S, Franco-Barraza J, Restifo D, Weitz N, Ogier C, Goldman AR, Hartman TR, Francescone R, Tan Y, Nicolas E, Shah N, Handorf EA, Cai KQ, O'Reilly AM, Sloma I, Chiaverelli R, Moffitt RA, Khazak V, Fang CY, Golemis EA, Cukierman E, Astsaturov I. Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer. Cancer Cell 2020;38:567-583.e11. [PMID: 32976774 DOI: 10.1016/j.ccell.2020.08.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
137 Kadera BE, Toste PA, Wu N, Li L, Nguyen AH, Dawson DW, Donahue TR. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin Cancer Res. 2015;21:157-165. [PMID: 25348515 DOI: 10.1158/1078-0432.ccr-14-0610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
138 Martens S, Lefesvre P, Nicolle R, Biankin A, Puleo F, Van Laethem J, Rooman I. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Annals of Oncology 2019;30:1428-36. [DOI: 10.1093/annonc/mdz181] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 11.5] [Reference Citation Analysis]
139 Zhao L, Lee VHF, Ng MK, Yan H, Bijlsma MF. Molecular subtyping of cancer: current status and moving toward clinical applications. Brief Bioinform 2019;20:572-84. [PMID: 29659698 DOI: 10.1093/bib/bby026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 21.0] [Reference Citation Analysis]
140 Diaferia GR, Balestrieri C, Prosperini E, Nicoli P, Spaggiari P, Zerbi A, Natoli G. Dissection of transcriptional and cis-regulatory control of differentiation in human pancreatic cancer. EMBO J 2016;35:595-617. [PMID: 26769127 DOI: 10.15252/embj.201592404] [Cited by in Crossref: 74] [Cited by in F6Publishing: 57] [Article Influence: 14.8] [Reference Citation Analysis]
141 Chopra N, Choudhury S, Bhargava S, Wajid S, Ganguly NK. Potentials of "stem cell-therapy" in pancreatic cancer: An update. Pancreatology. 2019;19:1034-1042. [PMID: 31668563 DOI: 10.1016/j.pan.2019.09.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
142 Lomberk G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, Mathison A, Sun Z, Yan H, Elarouci N, Armenoult L, Ayadi M, Ordog T, Lee JH, Oliver G, Klee E, Moutardier V, Gayet O, Bian B, Duconseil P, Gilabert M, Bigonnet M, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Secq V, De Reyniès A, Dusetti N, Iovanna J, Urrutia R. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun 2018;9:1978. [PMID: 29773832 DOI: 10.1038/s41467-018-04383-6] [Cited by in Crossref: 102] [Cited by in F6Publishing: 75] [Article Influence: 34.0] [Reference Citation Analysis]
143 Du Y, Zhao B, Liu Z, Ren X, Zhao W, Li Z, You L, Zhao Y. Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. J Cancer 2017;8:513-22. [PMID: 28367231 DOI: 10.7150/jca.17622] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
144 Huang H, Zou Y, Zhang H, Li X, Li Y, Deng X, Sun H, Guo Z, Ao L. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma. Transl Res 2020;219:30-44. [PMID: 32119844 DOI: 10.1016/j.trsl.2020.02.004] [Reference Citation Analysis]
145 Iovanna J. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Transl Oncol 2021;14:100965. [PMID: 33248412 DOI: 10.1016/j.tranon.2020.100965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
146 Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer. 2019;121:5-14. [PMID: 31110329 DOI: 10.1038/s41416-019-0479-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 22.0] [Reference Citation Analysis]
147 Pishvaian MJ, Blais EM, Brody JR, Rahib L, Lyons E, De Arbeloa P, Hendifar A, Mikhail S, Chung V, Sohal DP, Leslie S, Mason K, Tibbets L, Madhavan S, Matrisian LM, Petricoin E. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. JCO Precision Oncology 2019. [DOI: 10.1200/po.19.00115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
148 Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol 2020;17:487-505. [PMID: 32393771 DOI: 10.1038/s41575-020-0300-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 75.0] [Reference Citation Analysis]
149 Sheil CJ, Khan U, Zakharov YN, Coughlan MF, Pleskow DK, Sawhney MS, Berzin TM, Cohen JM, Glyavina M, Zhang L, Itzkan I, Perelman LT, Qiu L. Two-photon polymerization nanofabrication of ultracompact light scattering spectroscopic probe for detection of pre-cancer in pancreatic cyst. Opt Lasers Eng 2021;142:106616. [PMID: 34305200 DOI: 10.1016/j.optlaseng.2021.106616] [Reference Citation Analysis]
150 Russell R, Perkhofer L, Liebau S, Lin Q, Lechel A, Feld FM, Hessmann E, Gaedcke J, Güthle M, Zenke M, Hartmann D, von Figura G, Weissinger SE, Rudolph KL, Möller P, Lennerz JK, Seufferlein T, Wagner M, Kleger A. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat Commun 2015;6:7677. [PMID: 26220524 DOI: 10.1038/ncomms8677] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 9.8] [Reference Citation Analysis]
151 Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, Ruggero D, McCormick F. Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions. Cancer Res 2015;75:2851-62. [PMID: 25977330 DOI: 10.1158/0008-5472.CAN-14-1623] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
152 Li R, He Y, Zhang H, Wang J, Liu X, Liu H, Wu H, Liang Z. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Front Immunol 2021;12:690056. [PMID: 34335594 DOI: 10.3389/fimmu.2021.690056] [Reference Citation Analysis]
153 Leroux C, Konstantinidou G. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers (Basel) 2021;13:799. [PMID: 33672917 DOI: 10.3390/cancers13040799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
154 Yee NS. Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype. Adv Exp Med Biol 2013;779:91-143. [PMID: 23288637 DOI: 10.1007/978-1-4614-6176-0_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
155 Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47-52. [PMID: 26909576 DOI: 10.1038/nature16965] [Cited by in Crossref: 1525] [Cited by in F6Publishing: 1196] [Article Influence: 305.0] [Reference Citation Analysis]
156 Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology. 2012;142:1079-1092. [PMID: 22406637 DOI: 10.1053/j.gastro.2012.03.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 13.3] [Reference Citation Analysis]
157 Kloesch B, Ionasz V, Paliwal S, Hruschka N, Martinez de Villarreal J, Öllinger R, Mueller S, Dienes HP, Schindl M, Gruber ES, Stift J, Herndler-Brandstetter D, Lomberk GA, Seidler B, Saur D, Rad R, Urrutia RA, Real FX, Martinelli P. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Gut 2021:gutjnl-2020-321397. [PMID: 33846140 DOI: 10.1136/gutjnl-2020-321397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
158 Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 2019;14:141. [PMID: 31395068 DOI: 10.1186/s13014-019-1345-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 37.0] [Reference Citation Analysis]
159 Hu D, Ansari D, Zhou Q, Sasor A, Said Hilmersson K, Andersson R. Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma. Scand J Gastroenterol 2019;54:95-100. [PMID: 30663442 DOI: 10.1080/00365521.2018.1561937] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
160 Ling Q, Kalthoff H. Transportome Malfunctions and the Hallmarks of Pancreatic Cancer. Rev Physiol Biochem Pharmacol 2020. [PMID: 32770395 DOI: 10.1007/112_2020_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
161 Jungmann F, Kaissis GA, Ziegelmayer S, Harder F, Schilling C, Yen HY, Steiger K, Weichert W, Schirren R, Demir IE, Friess H, Makowski MR, Braren RF, Lohöfer FK. Prediction of Tumor Cellularity in Resectable PDAC from Preoperative Computed Tomography Imaging. Cancers (Basel) 2021;13:2069. [PMID: 33922981 DOI: 10.3390/cancers13092069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
162 Stone ML, Beatty GL. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Pharmacol Ther. 2019;201:202-213. [PMID: 31158393 DOI: 10.1016/j.pharmthera.2019.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
163 Sinn M, Striefler JK, Sinn BV, Sallmon D, Bischoff S, Stieler JM, Pelzer U, Bahra M, Neuhaus P, Dörken B, Denkert C, Riess H, Oettle H. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. J Surg Oncol 2013;108:398-402. [PMID: 24038103 DOI: 10.1002/jso.23409] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
164 Kaissis G, Ziegelmayer S, Lohöfer F, Algül H, Eiber M, Weichert W, Schmid R, Friess H, Rummeny E, Ankerst D, Siveke J, Braren R. A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. Eur Radiol Exp 2019;3:41. [PMID: 31624935 DOI: 10.1186/s41747-019-0119-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
165 Pitarresi JR, Norgard RJ, Chiarella AM, Suzuki K, Bakir B, Sahu V, Li J, Zhao J, Marchand B, Wengyn MD, Hsieh A, Kim IK, Zhang A, Sellin K, Lee V, Takano S, Miyahara Y, Ohtsuka M, Maitra A, Notta F, Kremer R, Stanger BZ, Rustgi AK. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Cancer Discov 2021;11:1774-91. [PMID: 33589425 DOI: 10.1158/2159-8290.CD-20-1098] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Kaissis GA, Jungmann F, Ziegelmayer S, Lohöfer FK, Harder FN, Schlitter AM, Muckenhuber A, Steiger K, Schirren R, Friess H, Schmid R, Weichert W, Makowski MR, Braren RF. Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters. J Clin Med 2020;9:E1250. [PMID: 32344944 DOI: 10.3390/jcm9051250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
167 Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol 2021:S1044-579X(21)00160-7. [PMID: 34062264 DOI: 10.1016/j.semcancer.2021.05.030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Sodergren MH, Mangal N, Wasan H, Sadanandam A, Balachandran VP, Jiao LR, Habib N. Immunological combination treatment holds the key to improving survival in pancreatic cancer. J Cancer Res Clin Oncol 2020;146:2897-911. [PMID: 32748119 DOI: 10.1007/s00432-020-03332-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
169 Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene. 2014;33:2454-2463. [PMID: 23752186 DOI: 10.1038/onc.2013.204] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
170 Seppälä TT, Zimmerman JW, Sereni E, Plenker D, Suri R, Rozich N, Blair A, Thomas DL 2nd, Teinor J, Javed A, Patel H, Cameron JL, Burns WR, He J, Tuveson DA, Jaffee EM, Eshleman J, Szabolcs A, Ryan DP, Ting DT, Wolfgang CL, Burkhart RA. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Ann Surg 2020;272:427-35. [PMID: 32657929 DOI: 10.1097/SLA.0000000000004200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
171 Tu B, Yao J, Ferri-Borgogno S, Zhao J, Chen S, Wang Q, Yan L, Zhou X, Zhu C, Bang S, Chang Q, Bristow CA, Kang Y, Zheng H, Wang H, Fleming JB, Kim M, Heffernan TP, Draetta GF, Pan D, Maitra A, Yao W, Gupta S, Ying H. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight 2019;4:130811. [PMID: 31557131 DOI: 10.1172/jci.insight.130811] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
172 Zhou Q, Andersson R, Hu D, Bauden M, Sasor A, Bygott T, PawŁowski K, Pla I, Marko-Varga G, Ansari D. Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis. Transl Res 2019;212:67-79. [PMID: 31295437 DOI: 10.1016/j.trsl.2019.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
173 Hamdan FH, Johnsen SA. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network. Proc Natl Acad Sci U S A 2018;115:E12343-52. [PMID: 30541891 DOI: 10.1073/pnas.1812915116] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 11.3] [Reference Citation Analysis]
174 Tiriac H, Plenker D, Baker LA, Tuveson DA. Organoid models for translational pancreatic cancer research. Curr Opin Genet Dev 2019;54:7-11. [PMID: 30844513 DOI: 10.1016/j.gde.2019.02.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
175 Camolotto SA, Belova VK, Snyder EL. The role of lineage specifiers in pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2018;9:1005-13. [PMID: 30603119 DOI: 10.21037/jgo.2018.05.04] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
176 Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res. 2012;11:1274-1283. [PMID: 22066465 DOI: 10.1021/pr200960u] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
177 Roy N, Takeuchi KK, Ruggeri JM, Bailey P, Chang D, Li J, Leonhardt L, Puri S, Hoffman MT, Gao S, Halbrook CJ, Song Y, Ljungman M, Malik S, Wright CV, Dawson DW, Biankin AV, Hebrok M, Crawford HC. PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Genes Dev. 2016;30:2669-2683. [PMID: 28087712 DOI: 10.1101/gad.291021.116] [Cited by in Crossref: 57] [Cited by in F6Publishing: 39] [Article Influence: 14.3] [Reference Citation Analysis]
178 Tyler M, Tirosh I. Decoupling epithelial-mesenchymal transitions from stromal profiles by integrative expression analysis. Nat Commun 2021;12:2592. [PMID: 33972543 DOI: 10.1038/s41467-021-22800-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018;8:1096-1111. [PMID: 29903880 DOI: 10.1158/2159-8290.cd-18-0275] [Cited by in Crossref: 113] [Cited by in F6Publishing: 63] [Article Influence: 37.7] [Reference Citation Analysis]
180 Martinez-Garcia R, Juan D, Rausell A, Muñoz M, Baños N, Menéndez C, Lopez-Casas PP, Rico D, Valencia A, Hidalgo M. Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med 2014;6:27. [PMID: 24739241 DOI: 10.1186/gm544] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
181 Colak S, Ten Dijke P. Targeting TGF-β Signaling in Cancer. Trends Cancer 2017;3:56-71. [PMID: 28718426 DOI: 10.1016/j.trecan.2016.11.008] [Cited by in Crossref: 312] [Cited by in F6Publishing: 279] [Article Influence: 78.0] [Reference Citation Analysis]
182 Martin ES, Belmont PJ, Sinnamon MJ, Richard LG, Yuan J, Coffee EM, Roper J, Lee L, Heidari P, Lunt SY, Goel G, Ji X, Xie Z, Xie T, Lamb J, Weinrich SL, VanArsdale T, Bronson RT, Xavier RJ, Vander Heiden MG, Kan JL, Mahmood U, Hung KE. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin Cancer Res 2013;19:2929-40. [PMID: 23403635 DOI: 10.1158/1078-0432.CCR-12-2307] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
183 Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, Quertinmont E, Svrcek M, Elarouci N, Iovanna J, Franchimont D, Verset L, Galdon MG, Devière J, de Reyniès A, Laurent-puig P, Van Laethem J, Bachet J, Maréchal R. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology 2018;155:1999-2013.e3. [DOI: 10.1053/j.gastro.2018.08.033] [Cited by in Crossref: 155] [Cited by in F6Publishing: 115] [Article Influence: 51.7] [Reference Citation Analysis]
184 Schneeweis C, Hassan Z, Schick M, Keller U, Schneider G. The SUMO pathway in pancreatic cancer: insights and inhibition. Br J Cancer 2021;124:531-8. [PMID: 33071285 DOI: 10.1038/s41416-020-01119-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
185 Li M, Li T, Ma W, Wang X, Zhao G. MicroRNA-608 promotes apoptosis via BRD4 downregulation in pancreatic ductal adenocarcinoma. Oncol Lett 2020;19:1418-26. [PMID: 32002032 DOI: 10.3892/ol.2019.11246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
186 Jamieson NB, Chan NI, Foulis AK, Dickson EJ, McKay CJ, Carter CR. The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17:511-521. [PMID: 23297028 DOI: 10.1007/s11605-012-2131-z] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
187 Lei Y, Tang R, Xu J, Wang W, Zhang B, Liu J, Yu X, Shi S. Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol 2021;14:91. [PMID: 34108022 DOI: 10.1186/s13045-021-01105-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Ponz-Sarvise M, Tuveson DA, Yu KH. Mouse Models of Pancreatic Ductal Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:609-17. [PMID: 26226900 DOI: 10.1016/j.hoc.2015.04.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
189 Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Timpson P. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Gastroenterology 2018;154:820-38. [PMID: 29287624 DOI: 10.1053/j.gastro.2017.11.280] [Cited by in Crossref: 98] [Cited by in F6Publishing: 81] [Article Influence: 24.5] [Reference Citation Analysis]
190 García-García AB, Gómez-Mateo MC, Hilario R, Rentero-Garrido P, Martínez-Domenech A, Gonzalez-Albert V, Cervantes A, Marín-Garcia P, Chaves FJ, Ferrández-Izquierdo A, Sabater L. mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival. Oncotarget 2017;8:104796-805. [PMID: 29285214 DOI: 10.18632/oncotarget.20076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
191 Huang W, Navarro-Serer B, Jeong YJ, Chianchiano P, Xia L, Luchini C, Veronese N, Dowiak C, Ng T, Trujillo MA, Huang B, Pflüger MJ, Macgregor-Das AM, Lionheart G, Jones D, Fujikura K, Nguyen-Ngoc KV, Neumann NM, Groot VP, Hasanain A, van Oosten AF, Fischer SE, Gallinger S, Singhi AD, Zureikat AH, Brand RE, Gaida MM, Heinrich S, Burkhart RA, He J, Wolfgang CL, Goggins MG, Thompson ED, Roberts NJ, Ewald AJ, Wood LD. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Cancer Res 2020;80:2804-17. [PMID: 32376602 DOI: 10.1158/0008-5472.CAN-19-1523] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
192 Dreyer SB, Jamieson NB, Upstill-Goddard R, Bailey PJ, McKay CJ, Biankin AV, Chang DK; Australian Pancreatic Cancer Genome Initiative. Defining the molecular pathology of pancreatic body and tail adenocarcinoma. Br J Surg 2018;105:e183-91. [PMID: 29341146 DOI: 10.1002/bjs.10772] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 17.0] [Reference Citation Analysis]
193 Trajkovic-Arsic M, Heid I, Steiger K, Gupta A, Fingerle A, Wörner C, Teichmann N, Sengkwawoh-Lueong S, Wenzel P, Beer AJ, Esposito I, Braren R, Siveke JT. Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. Sci Rep 2017;7:17038. [PMID: 29213099 DOI: 10.1038/s41598-017-16826-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
194 Parkin A, Man J, Timpson P, Pajic M. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS J 2019;286:3510-39. [PMID: 31330086 DOI: 10.1111/febs.15011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
195 Young K, Lawlor RT, Ragulan C, Patil Y, Mafficini A, Bersani S, Antonello D, Mansfield D, Cingarlini S, Landoni L, Pea A, Luchini C, Piredda L, Kannan N, Nyamundanda G, Morganstein D, Chau I, Wiedenmann B, Milella M, Melcher A, Cunningham D, Starling N, Scarpa A, Sadanandam A. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut 2021;70:1904-13. [PMID: 32883872 DOI: 10.1136/gutjnl-2020-321016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
196 Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. Biochim Biophys Acta Rev Cancer 2018;1869:248-55. [PMID: 29499330 DOI: 10.1016/j.bbcan.2018.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
197 Martinez-Useros J, Martin-Galan M, Garcia-Foncillas J. The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance. Cancers (Basel) 2021;13:322. [PMID: 33477288 DOI: 10.3390/cancers13020322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
198 Kumar N, Cramer GM, Dahaj SAZ, Sundaram B, Celli JP, Kulkarni RV. Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations. Sci Rep 2019;9:10845. [PMID: 31350465 DOI: 10.1038/s41598-019-46926-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
199 Gomi F, Sasaki N, Shichi Y, Minami F, Shinji S, Toyoda M, Ishiwata T. Polyvinyl alcohol increased growth, migration, invasion, and sphere size in the PK-8 pancreatic ductal adenocarcinoma cell line. Heliyon 2021;7:e06182. [PMID: 33598581 DOI: 10.1016/j.heliyon.2021.e06182] [Reference Citation Analysis]
200 Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, Ohta Y, Matano M, Nanki K, Kawasaki K, Takahashi S, Sugimoto S, Iwasaki E, Takagi J, Itoi T, Kitago M, Kitagawa Y, Kanai T, Sato T. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. Cell Stem Cell. 2018;22:454-467.e6. [PMID: 29337182 DOI: 10.1016/j.stem.2017.12.009] [Cited by in Crossref: 201] [Cited by in F6Publishing: 180] [Article Influence: 67.0] [Reference Citation Analysis]
201 Lee SW, Zhang Y, Jung M, Cruz N, Alas B, Commisso C. EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis. Dev Cell 2019;50:381-392.e5. [PMID: 31257175 DOI: 10.1016/j.devcel.2019.05.043] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 20.5] [Reference Citation Analysis]
202 Liu R, Liao YZ, Zhang W, Zhou HH. Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes. Front Oncol 2020;10:575264. [PMID: 33489882 DOI: 10.3389/fonc.2020.575264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
203 Gallego J, López C, Pazo-cid R, López-ríos F, Carrato A. Biomarkers in pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017;19:1430-7. [DOI: 10.1007/s12094-017-1691-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
204 N Kalimuthu S, Wilson GW, Grant RC, Seto M, O'Kane G, Vajpeyi R, Notta F, Gallinger S, Chetty R. Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome. Gut 2020;69:317-28. [PMID: 31201285 DOI: 10.1136/gutjnl-2019-318217] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
205 Jandaghi P, Najafabadi HS, Bauer AS, Papadakis AI, Fassan M, Hall A, Monast A, von Knebel Doeberitz M, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Sipos B, Auld D, Lathrop M, Park M, Büchler MW, Strobel O, Hackert T, Giese NA, Zogopoulos G, Sangwan V, Huang S, Riazalhosseini Y, Hoheisel JD. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Gastroenterology 2016;151:1218-31. [PMID: 27578530 DOI: 10.1053/j.gastro.2016.08.040] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
206 Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, Zhang T, Dai M, Zhao Y. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett 2021;520:1-11. [PMID: 34216688 DOI: 10.1016/j.canlet.2021.06.027] [Reference Citation Analysis]
207 Lu S, Ahmed T, Du P, Wang Y. Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. Int J Mol Sci 2017;18:E1201. [PMID: 28587243 DOI: 10.3390/ijms18061201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
208 Verbeke C. Morphological heterogeneity in ductal adenocarcinoma of the pancreas - Does it matter? Pancreatology. 2016;16:295-301. [PMID: 26924665 DOI: 10.1016/j.pan.2016.02.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
209 Li L, Hanahan D. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell 2013;153:86-100. [PMID: 23540692 DOI: 10.1016/j.cell.2013.02.051] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 9.8] [Reference Citation Analysis]
210 Whittle MC, Hingorani SR. Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets. Gastroenterology 2019;156:2085-96. [PMID: 30721663 DOI: 10.1053/j.gastro.2018.12.044] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 19.0] [Reference Citation Analysis]
211 Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355-385. [PMID: 26883357 DOI: 10.1101/gad.275776.115] [Cited by in Crossref: 241] [Cited by in F6Publishing: 205] [Article Influence: 48.2] [Reference Citation Analysis]
212 Ungefroren H, Sebens S, Giehl K, Helm O, Groth S, Fändrich F, Röcken C, Sipos B, Lehnert H, Gieseler F. Rac1b negatively regulates TGF-β1-induced cell motility in pancreatic ductal epithelial cells by suppressing Smad signalling. Oncotarget 2014;5:277-90. [PMID: 24378395 DOI: 10.18632/oncotarget.1696] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
213 Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, García-foncillas J, Grávalos C, Laquente B, Pericay C, Rivera F, Tabernero J, Aranda E. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clin Transl Oncol 2014;16:865-78. [DOI: 10.1007/s12094-014-1177-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
214 Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017;19:518-529. [PMID: 28414315 DOI: 10.1038/ncb3513] [Cited by in Crossref: 406] [Cited by in F6Publishing: 358] [Article Influence: 101.5] [Reference Citation Analysis]
215 Wang J, Yang S, He P, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, Hanna N, Alexander HR, Hussain SP. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Clin Cancer Res 2016;22:5992-6001. [PMID: 27401251 DOI: 10.1158/1078-0432.CCR-16-0511] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
216 Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today 2020;50:1117-25. [PMID: 32474642 DOI: 10.1007/s00595-020-02028-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
217 Reichert M, Bakir B, Moreira L, Pitarresi JR, Feldmann K, Simon L, Suzuki K, Maddipati R, Rhim AD, Schlitter AM, Kriegsmann M, Weichert W, Wirth M, Schuck K, Schneider G, Saur D, Reynolds AB, Klein-Szanto AJ, Pehlivanoglu B, Memis B, Adsay NV, Rustgi AK. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Dev Cell 2018;45:696-711.e8. [PMID: 29920275 DOI: 10.1016/j.devcel.2018.05.025] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 20.3] [Reference Citation Analysis]
218 Grant TJ, Mehta AK, Gupta A, Sharif AAD, Arora KS, Deshpande V, Ting DT, Bardeesy N, Ganem NJ, Hergovich A, Singh A. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget 2017;8:78556-72. [PMID: 29108249 DOI: 10.18632/oncotarget.20833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
219 Ohm AM, Tan AC, Heasley LE, Reyland ME. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. Oncogene 2017;36:4370-8. [PMID: 28368426 DOI: 10.1038/onc.2017.27] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
220 Smithy JW, O'Reilly EM. Pancreas cancer: Therapeutic trials in metastatic disease. J Surg Oncol 2021;123:1475-88. [PMID: 33831245 DOI: 10.1002/jso.26359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
221 Nyamundanda G, Eason K, Guinney J, Lord CJ, Sadanandam A. A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine. Cancers (Basel) 2020;12:E2811. [PMID: 33007815 DOI: 10.3390/cancers12102811] [Reference Citation Analysis]
222 Mannarapu M, Dariya B, Bandapalli OR. Application of single-cell sequencing technologies in pancreatic cancer. Mol Cell Biochem 2021;476:2429-37. [PMID: 33599893 DOI: 10.1007/s11010-021-04095-4] [Reference Citation Analysis]
223 Cox JL, Wilder PJ, Wuebben EL, Ouellette MM, Hollingsworth MA, Rizzino A. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma. Cancer Biol Ther 2014;15:1042-52. [PMID: 24841553 DOI: 10.4161/cbt.29182] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
224 Kong L, Liu P, Zheng M, Xue B, Liang K, Tan X. Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer. Epigenomics 2020;12:507-24. [PMID: 32048534 DOI: 10.2217/epi-2019-0374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
225 Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159:80-93. [PMID: 25259922 DOI: 10.1016/j.cell.2014.08.007] [Cited by in Crossref: 560] [Cited by in F6Publishing: 497] [Article Influence: 93.3] [Reference Citation Analysis]
226 Kondratyeva LG, Sveshnikova AA, Grankina EV, Chernov IP, Kopantseva MR, Kopantzev EP, Sverdlov ED. Downregulation of expression of mater genes SOX9, FOXA2, and GATA4 in pancreatic cancer cells stimulated with TGFβ1 epithelial-mesenchymal transition. Dokl Biochem Biophys 2016;469:257-9. [PMID: 27599506 DOI: 10.1134/S1607672916040062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
227 Kong B, Wu W, Valkovska N, Jäger C, Hong X, Nitsche U, Friess H, Esposito I, Erkan M, Kleeff J, Michalski CW. A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels. Sci Rep 2015;5:8109. [PMID: 25657029 DOI: 10.1038/srep08109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
228 Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O'Kane GM, Connor AA, Denroche RE, Grant RC, McLeod J, Wilson JM, Jang GH, Zhang A, Dodd A, Liang SB, Borgida A, Chadwick D, Kalimuthu S, Lungu I, Bartlett JMS, Krzyzanowski PM, Sandhu V, Tiriac H, Froeling FEM, Karasinska JM, Topham JT, Renouf DJ, Schaeffer DF, Jones SJM, Marra MA, Laskin J, Chetty R, Stein LD, Zogopoulos G, Haibe-Kains B, Campbell PJ, Tuveson DA, Knox JJ, Fischer SE, Gallinger S, Notta F. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet 2020;52:231-40. [PMID: 31932696 DOI: 10.1038/s41588-019-0566-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 71] [Article Influence: 106.0] [Reference Citation Analysis]
229 Holbrook MC, Goad DW, Grdzelishvili VZ. Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions. Cancers (Basel) 2021;13:1171. [PMID: 33803211 DOI: 10.3390/cancers13051171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Karimnia V, Rizvi I, Slack FJ, Celli JP. Photodestruction of Stromal Fibroblasts Enhances Tumor Response to PDT in 3D Pancreatic Cancer Coculture Models. Photochem Photobiol 2021;97:416-26. [PMID: 33011973 DOI: 10.1111/php.13339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Gendoo DMA. Bioinformatics and computational approaches for analyzing patient-derived disease models in cancer research. Comput Struct Biotechnol J 2020;18:375-80. [PMID: 32128067 DOI: 10.1016/j.csbj.2020.01.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
232 Sinha S, Leach SD. New insights in the development of pancreatic cancer. Curr Opin Gastroenterol. 2016;32:394-400. [PMID: 27454028 DOI: 10.1097/mog.0000000000000295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
233 Słotwiński R, Słotwińska SM. Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer. Cent Eur J Immunol 2016;41:392-403. [PMID: 28450803 DOI: 10.5114/ceji.2016.65139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
234 Ling B, Huang Z, Huang S, Qian L, Li G, Tang Q. Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma. Oncol Res 2021;28:561-78. [PMID: 32471520 DOI: 10.3727/096504020X15907428281601] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
235 Siveke JT, Crawford HC. KRAS above and beyond - EGFR in pancreatic cancer. Oncotarget. 2012;3:1262-1263. [PMID: 23174662 DOI: 10.18632/oncotarget.750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
236 Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. Int J Cancer 2018;143:179-83. [PMID: 29396858 DOI: 10.1002/ijc.31292] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
237 Tzatsos A, Paskaleva P, Ferrari F, Deshpande V, Stoykova S, Contino G, Wong KK, Lan F, Trojer P, Park PJ, Bardeesy N. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest 2013;123:727-39. [PMID: 23321669 DOI: 10.1172/JCI64535] [Cited by in Crossref: 27] [Cited by in F6Publishing: 71] [Article Influence: 3.4] [Reference Citation Analysis]
238 Kothari V, Wei I, Shankar S, Kalyana-Sundaram S, Wang L, Ma LW, Vats P, Grasso CS, Robinson DR, Wu YM, Cao X, Simeone DM, Chinnaiyan AM, Kumar-Sinha C. Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov 2013;3:280-93. [PMID: 23384775 DOI: 10.1158/2159-8290.CD-12-0336] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
239 Venkat S, Tisdale AA, Schwarz JR, Alahmari AA, Maurer HC, Olive KP, Eng KH, Feigin ME. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. Genome Res 2020;30:347-60. [PMID: 32029502 DOI: 10.1101/gr.257550.119] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
240 Lee H, Choi B, Kang HN, Kim H, Min A, Cha M, Ryu JY, Park S, Sohn J, Shin K, Yun MR, Han JY, Shon MJ, Jeong C, Chung J, Lee S, Im S, Cho BC, Yoon T. Profiling of protein–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Nat Biomed Eng 2018;2:239-53. [DOI: 10.1038/s41551-018-0212-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
241 Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, Johnson BD, Mackinnon A, Hessner MJ, Gershan JA. A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis. Cancer Epidemiol Biomarkers Prev 2019;28:680-9. [PMID: 30530849 DOI: 10.1158/1055-9965.EPI-18-0813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
242 Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Front Immunol 2018;9:1878. [PMID: 30158932 DOI: 10.3389/fimmu.2018.01878] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 16.3] [Reference Citation Analysis]
243 Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91-100. [PMID: 24388967 DOI: 10.1016/j.tibs.2013.12.004] [Cited by in Crossref: 375] [Cited by in F6Publishing: 332] [Article Influence: 53.6] [Reference Citation Analysis]
244 Dantes Z, Yen HY, Pfarr N, Winter C, Steiger K, Muckenhuber A, Hennig A, Lange S, Engleitner T, Öllinger R, Maresch R, Orben F, Heid I, Kaissis G, Shi K, Topping G, Stögbauer F, Wirth M, Peschke K, Papargyriou A, Rezaee-Oghazi M, Feldmann K, Schäfer AP, Ranjan R, Lubeseder-Martellato C, Stange DE, Welsch T, Martignoni M, Ceyhan GO, Friess H, Herner A, Liotta L, Treiber M, von Figura G, Abdelhafez M, Klare P, Schlag C, Algül H, Siveke J, Braren R, Weirich G, Weichert W, Saur D, Rad R, Schmid RM, Schneider G, Reichert M. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. JCI Insight 2020;5:137809. [PMID: 32614802 DOI: 10.1172/jci.insight.137809] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
245 Tsuboi M, Taniuchi K, Shimizu T, Saito M, Saibara T. The transcription factor HOXB7 regulates ERK kinase activity and thereby stimulates the motility and invasiveness of pancreatic cancer cells. J Biol Chem 2017;292:17681-702. [PMID: 28912272 DOI: 10.1074/jbc.M116.772780] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
246 Singh S, Hasselluhn MC, Neesse A. A tangled tale of molecular subtypes in pancreatic cancer. Gut 2019;68:953-4. [DOI: 10.1136/gutjnl-2018-318086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
247 Milan M, Diaferia GR, Natoli G. Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: a tale of two cell types and their many variants. EMBO J 2021;40:e107206. [PMID: 33844319 DOI: 10.15252/embj.2020107206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
248 Luo L, McGarvey P, Madhavan S, Kumar R, Gusev Y, Upadhyay G. Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome. Oncotarget 2016;7:11165-93. [PMID: 26862846 DOI: 10.18632/oncotarget.7163] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
249 Roy S, Singh AP, Gupta D. Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma. Heliyon 2021;7:e06000. [PMID: 33521362 DOI: 10.1016/j.heliyon.2021.e06000] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
250 Hung SW, Mody HR, Govindarajan R. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett. 2012;320:138-149. [PMID: 22425961 DOI: 10.1016/j.canlet.2012.03.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
251 Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19:619-625. [PMID: 23584089 DOI: 10.1038/nm.3175] [Cited by in Crossref: 597] [Cited by in F6Publishing: 505] [Article Influence: 74.6] [Reference Citation Analysis]
252 Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Ann Surg 2020. [PMID: 32398486 DOI: 10.1097/SLA.0000000000003945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
253 Chen DT, Davis-Yadley AH, Huang PY, Husain K, Centeno BA, Permuth-Wey J, Pimiento JM, Malafa M. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma. PLoS One 2015;10:e0133562. [PMID: 26247463 DOI: 10.1371/journal.pone.0133562] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
254 Birnbaum DJ, Finetti P, Birnbaum D, Mamessier E, Bertucci F. Validation and comparison of the molecular classifications of pancreatic carcinomas. Mol Cancer 2017;16:168. [PMID: 29110659 DOI: 10.1186/s12943-017-0739-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
255 Kharin L, Bychkov I, Karnaukhov N, Voloshin M, Fazliyeva R, Deneka A, Frantsiyants E, Kit O, Golemis E, Boumber Y. Prognostic role and biologic features of Musashi-2 expression in colon polyps and during colorectal cancer progression. PLoS One 2021;16:e0252132. [PMID: 34237057 DOI: 10.1371/journal.pone.0252132] [Reference Citation Analysis]
256 Yu K, Chen B, Aran D, Charalel J, Yau C, Wolf DM, van 't Veer LJ, Butte AJ, Goldstein T, Sirota M. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nat Commun 2019;10:3574. [PMID: 31395879 DOI: 10.1038/s41467-019-11415-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 20.0] [Reference Citation Analysis]
257 Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014;74:5057-69. [PMID: 25082815 DOI: 10.1158/0008-5472.CAN-13-3723] [Cited by in Crossref: 630] [Cited by in F6Publishing: 412] [Article Influence: 90.0] [Reference Citation Analysis]
258 Steins A, van Mackelenbergh MG, van der Zalm AP, Klaassen R, Serrels B, Goris SG, Kocher HM, Waasdorp C, de Jong JH, Tekin C, Besselink MG, Busch OR, van de Vijver MJ, Verheij J, Dijk F, van Tienhoven G, Wilmink JW, Medema JP, van Laarhoven HW, Bijlsma MF. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. EMBO Rep 2020;21:e48780. [PMID: 32173982 DOI: 10.15252/embr.201948780] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
259 Dorado J, Lonardo E, Miranda-Lorenzo I, Heeschen C. Pancreatic cancer stem cells: new insights and perspectives. J Gastroenterol. 2011;46:966-973. [PMID: 21698355 DOI: 10.1007/s00535-011-0422-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
260 Kim Y, Kim D, Cao B, Carvajal R, Kim M. PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients. BMC Bioinformatics 2020;21:288. [PMID: 32631229 DOI: 10.1186/s12859-020-03633-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
261 Jiang W, Zhang Y, Kane KT, Collins MA, Simeone DM, di Magliano MP, Nguyen KT. CD44 regulates pancreatic cancer invasion through MT1-MMP. Mol Cancer Res. 2015;13:9-15. [PMID: 25566991 DOI: 10.1158/1541-7786.mcr-14-0076] [Cited by in Crossref: 51] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
262 Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9:77-87. [PMID: 22183185 DOI: 10.1038/nrgastro.2011.215] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
263 Hasan N, Ahuja N. The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer. Cancers (Basel) 2019;11:E1859. [PMID: 31769422 DOI: 10.3390/cancers11121859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
264 Ai J, Wörmann SM, Görgülü K, Vallespinos M, Zagorac S, Alcala S, Wu N, Kabacaoglu D, Berninger A, Navarro D, Kaya-Aksoy E, Ruess DA, Ciecielski KJ, Kowalska M, Demir IE, Ceyhan GO, Heid I, Braren R, Riemann M, Schreiner S, Hofmann S, Kutschke M, Jastroch M, Slotta-Huspenina J, Muckenhuber A, Schlitter AM, Schmid RM, Steiger K, Diakopoulos KN, Lesina M, Sainz B Jr, Algül H. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Gastroenterology 2021;161:318-332.e9. [PMID: 33819482 DOI: 10.1053/j.gastro.2021.03.051] [Reference Citation Analysis]
265 Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111:817-822. [PMID: 24755884 DOI: 10.1038/bjc.2014.215] [Cited by in Crossref: 304] [Cited by in F6Publishing: 275] [Article Influence: 43.4] [Reference Citation Analysis]
266 Hu HF, Ye Z, Qin Y, Xu XW, Yu XJ, Zhuo QF, Ji SR. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol Sin 2021. [PMID: 33574569 DOI: 10.1038/s41401-020-00584-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Brabletz T. To differentiate or not--routes towards metastasis. Nat Rev Cancer. 2012;12:425-436. [PMID: 22576165 DOI: 10.1038/nrc3265] [Cited by in Crossref: 402] [Cited by in F6Publishing: 370] [Article Influence: 44.7] [Reference Citation Analysis]
268 Regel I, Mayerle J, Mahajan UM. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer. Cancers (Basel) 2020;12:E1024. [PMID: 32326341 DOI: 10.3390/cancers12041024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
269 Jahan R, Shah A, Kisling SG, Macha MA, Thayer S, Batra SK, Kaur S. Odyssey of trefoil factors in cancer: Diagnostic and therapeutic implications. Biochim Biophys Acta Rev Cancer 2020;1873:188362. [PMID: 32298747 DOI: 10.1016/j.bbcan.2020.188362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
270 Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, Lübbert M, Puhr M, Culig Z, Wellner U, Keck T, Bronsert P, Küsters S, Hopt UT, Stemmler MP, Brabletz T. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med 2015;7:831-47. [PMID: 25872941 DOI: 10.15252/emmm.201404396] [Cited by in Crossref: 129] [Cited by in F6Publishing: 110] [Article Influence: 25.8] [Reference Citation Analysis]
271 Zhu QN, Renaud H, Guo Y. Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy. Hereditas 2018;155:17. [PMID: 29371858 DOI: 10.1186/s41065-018-0055-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
272 Aravindan S, Delma CR, Thirugnanasambandan SS, Herman TS, Aravindan N. Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae. PLoS One 2013;8:e61977. [PMID: 23613993 DOI: 10.1371/journal.pone.0061977] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
273 Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020;130:4704-4709. [PMID: 32749238 DOI: 10.1172/jci136760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 20.0] [Reference Citation Analysis]
274 Verbeke C, Häberle L, Lenggenhager D, Esposito I. Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. Pancreatology 2018;18:467-76. [PMID: 29843972 DOI: 10.1016/j.pan.2018.04.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
275 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 25.0] [Reference Citation Analysis]
276 Beatty GL, Werba G, Lyssiotis CA, Simeone DM. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev 2021;35:940-62. [PMID: 34117095 DOI: 10.1101/gad.348523.121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
277 Hayashi H, Higashi T, Miyata T, Yamashita YI, Baba H. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:457-66. [PMID: 34337294 DOI: 10.1002/ags3.12436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Cheng WY, Ou Yang TH, Anastassiou D. Biomolecular events in cancer revealed by attractor metagenes. PLoS Comput Biol 2013;9:e1002920. [PMID: 23468608 DOI: 10.1371/journal.pcbi.1002920] [Cited by in Crossref: 75] [Cited by in F6Publishing: 57] [Article Influence: 9.4] [Reference Citation Analysis]
279 Mattheolabakis G, Papayannis I, Yang J, Vaeth BM, Wang R, Bandovic J, Ouyang N, Rigas B, Mackenzie GG. Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice. Cancer Prev Res (Phila) 2016;9:624-34. [PMID: 27138793 DOI: 10.1158/1940-6207.CAPR-15-0344] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
280 Cheng P, Phillips E, Kim SH, Taylor D, Hielscher T, Puccio L, Hjelmeland AB, Lichter P, Nakano I, Goidts V. Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Reports 2015;4:899-913. [PMID: 25921812 DOI: 10.1016/j.stemcr.2015.03.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
281 Ansari D, Friess H, Bauden M, Samnegård J, Andersson R. Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment. Oncotarget 2018;9:6644-51. [PMID: 29464100 DOI: 10.18632/oncotarget.24019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
282 Espiau-Romera P, Courtois S, Parejo-Alonso B, Sancho P. Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification.J Clin Med. 2020;9. [PMID: 33371431 DOI: 10.3390/jcm9124128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
283 Ramya Devi KT, Karthik D, Mahendran T, Jaganathan MK, Hemdev SP. Long noncoding RNAs: role and contribution in pancreatic cancer. Transcription 2021;12:12-27. [PMID: 34036896 DOI: 10.1080/21541264.2021.1922071] [Reference Citation Analysis]
284 Haeberle L, Esposito I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:50. [PMID: 31304427 DOI: 10.21037/tgh.2019.06.02] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 15.5] [Reference Citation Analysis]
285 Ward EP, Evans DB, Tsai S. Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. J Surg Oncol 2021;123:1405-13. [PMID: 33831252 DOI: 10.1002/jso.26395] [Reference Citation Analysis]
286 Milton CK, Self AJ, Clarke PA, Banerji U, Piccioni F, Root DE, Whittaker SR. A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer. Mol Cancer Ther 2020;19:1423-35. [PMID: 32371585 DOI: 10.1158/1535-7163.MCT-19-1131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
287 Sereti E, Karagianellou T, Kotsoni I, Magouliotis D, Kamposioras K, Ulukaya E, Sakellaridis N, Zacharoulis D, Dimas K. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer? J Proteomics 2018;188:107-18. [PMID: 29398619 DOI: 10.1016/j.jprot.2018.01.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
288 Norberg KJ, Liu X, Fernández Moro C, Strell C, Nania S, Blümel M, Balboni A, Bozóky B, Heuchel RL, Löhr JM. A novel pancreatic tumour and stellate cell 3D co-culture spheroid model. BMC Cancer 2020;20:475. [PMID: 32460715 DOI: 10.1186/s12885-020-06867-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
289 Collins MA, Brisset JC, Zhang Y, Bednar F, Pierre J, Heist KA, Galbán CJ, Galbán S, di Magliano MP. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One 2012;7:e49707. [PMID: 23226501 DOI: 10.1371/journal.pone.0049707] [Cited by in Crossref: 111] [Cited by in F6Publishing: 94] [Article Influence: 12.3] [Reference Citation Analysis]
290 Pompella L, Tirino G, Pappalardo A, Caterino M, Ventriglia A, Nacca V, Orditura M, Ciardiello F, De Vita F. Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. Int J Mol Sci 2020;21:E2814. [PMID: 32316602 DOI: 10.3390/ijms21082814] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
291 Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008-2020. [PMID: 32593337 DOI: 10.1016/S0140-6736(20)30974-0] [Cited by in Crossref: 142] [Cited by in F6Publishing: 40] [Article Influence: 142.0] [Reference Citation Analysis]
292 de Oliveira G, Freire PP, Cury SS, de Moraes D, Oliveira JS, Dal-Pai-Silva M, Reis PP, Carvalho RF. An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2020;12:716. [PMID: 32197468 DOI: 10.3390/cancers12030716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
293 Moschovis D, Gazouli M, Tzouvala M, Vezakis A, Karamanolis G. Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors. Ann Gastroenterol 2017;30:622-8. [PMID: 29118556 DOI: 10.20524/aog.2017.0185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
294 Gooden HM, White KJ. Pancreatic cancer and supportive care--pancreatic exocrine insufficiency negatively impacts on quality of life. Support Care Cancer. 2013;21:1835-1841. [PMID: 23397095 DOI: 10.1007/s00520-013-1729-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
295 Biankin A, Maitra A. Subtyping Pancreatic Cancer. Cancer Cell 2015;28:411-3. [DOI: 10.1016/j.ccell.2015.09.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
296 Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol Cancer Res 2016;14:3-13. [PMID: 26248648 DOI: 10.1158/1541-7786.MCR-15-0189] [Cited by in Crossref: 145] [Cited by in F6Publishing: 73] [Article Influence: 24.2] [Reference Citation Analysis]
297 Liu B, Yang H, Taher L, Denz A, Grützmann R, Pilarsky C, Weber GF. Identification of Prognostic Biomarkers by Combined mRNA and miRNA Expression Microarray Analysis in Pancreatic Cancer. Transl Oncol 2018;11:700-14. [PMID: 29631214 DOI: 10.1016/j.tranon.2018.03.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
298 Hackeng WM, Hruban RH, Offerhaus GJ, Brosens LA. Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol 2016;11:47. [PMID: 27267993 DOI: 10.1186/s13000-016-0497-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 11.6] [Reference Citation Analysis]
299 Werner HM, Mills GB, Ram PT. Cancer Systems Biology: a peek into the future of patient care? Nat Rev Clin Oncol 2014;11:167-76. [PMID: 24492837 DOI: 10.1038/nrclinonc.2014.6] [Cited by in Crossref: 112] [Cited by in F6Publishing: 73] [Article Influence: 16.0] [Reference Citation Analysis]
300 Duan K, Jang GH, Grant RC, Wilson JM, Notta F, O'Kane GM, Knox JJ, Gallinger S, Fischer S. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Sci Rep 2021;11:14951. [PMID: 34294813 DOI: 10.1038/s41598-021-94544-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
301 Arner EN, Du W, Brekken RA. Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. Front Oncol 2019;9:1049. [PMID: 31681587 DOI: 10.3389/fonc.2019.01049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
302 Samain R, Brunel A, Douché T, Fanjul M, Cassant-Sourdy S, Rochotte J, Cros J, Neuzillet C, Raffenne J, Duluc C, Perraud A, Nigri J, Gigoux V, Bieche I, Ponzo M, Carpentier G, Cascone I, Tomasini R, Schmid HA, Mathonnet M, Nicolle R, Bousquet MP, Martineau Y, Pyronnet S, Jean C, Bousquet C. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Cell Mol Gastroenterol Hepatol 2021;11:1405-36. [PMID: 33482394 DOI: 10.1016/j.jcmgh.2021.01.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
303 Tan DJ, Mitra M, Chiu AM, Coller HA. Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma. NPJ Genom Med 2020;5:55. [PMID: 33311498 DOI: 10.1038/s41525-020-00159-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
304 Park E, Yoo JE, Hwang HK, Kang CM, Lee CK, Kim MH, Bang S, Park YN. Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2021. [PMID: 34318617 DOI: 10.1002/jhbp.1025] [Reference Citation Analysis]
305 Chen PY, Muzumdar MD, Dorans KJ, Robbins R, Bhutkar A, Del Rosario A, Mertins P, Qiao J, Schafer AC, Gertler F, Carr S, Jacks T. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res 2018;78:985-1002. [PMID: 29279356 DOI: 10.1158/0008-5472.CAN-17-2129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
306 Zhou Z, Zhang J, Xu C, Yang J, Zhang Y, Liu M, Shi X, Li X, Zhan H, Chen W, McNally LR, Fung KM, Luo W, Houchen CW, He Y, Zhang C, Li M. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine 2021;65:103271. [PMID: 33714027 DOI: 10.1016/j.ebiom.2021.103271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
307 Beutel AK, Schütte L, Scheible J, Roger E, Müller M, Perkhofer L, Kestler AMTU, Kraus JM, Kestler HA, Barth TFE, Lemke J, Kornmann M, Ettrich TJ, Gout J, Seufferlein T, Kleger A. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Cancers (Basel) 2021;13:2539. [PMID: 34064221 DOI: 10.3390/cancers13112539] [Reference Citation Analysis]
308 Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Yeh JJ. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 2015;47:1168-78. [PMID: 26343385 DOI: 10.1038/ng.3398] [Cited by in Crossref: 765] [Cited by in F6Publishing: 600] [Article Influence: 127.5] [Reference Citation Analysis]
309 Schlitter AM, Segler A, Steiger K, Michalski CW, Jäger C, Konukiewitz B, Pfarr N, Endris V, Bettstetter M, Kong B, Regel I, Kleeff J, Klöppel G, Esposito I. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Sci Rep 2017;7:41064. [PMID: 28145465 DOI: 10.1038/srep41064] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
310 Masugi Y, Abe T, Ueno A, Fujii-Nishimura Y, Ojima H, Endo Y, Fujita Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M. Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival. Mod Pathol 2019;32:1495-507. [PMID: 31186528 DOI: 10.1038/s41379-019-0291-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
311 Dorn A, Glaß M, Neu CT, Heydel B, Hüttelmaier S, Gutschner T, Haemmerle M. LINC00261 Is Differentially Expressed in Pancreatic Cancer Subtypes and Regulates a Pro-Epithelial Cell Identity. Cancers (Basel) 2020;12:E1227. [PMID: 32414223 DOI: 10.3390/cancers12051227] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
312 Naso JR, Topham JT, Karasinska JM, Lee MKC, Kalloger SE, Wong HL, Nelson J, Moore RA, Mungall AJ, Jones SJM, Laskin J, Marra MA, Renouf DJ, Schaeffer DF. Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. Cancer Med 2021;10:1155-65. [PMID: 33372414 DOI: 10.1002/cam4.3695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
313 Sinkala M, Mulder N, Martin D. Machine Learning and Network Analyses Reveal Disease Subtypes of Pancreatic Cancer and their Molecular Characteristics. Sci Rep. 2020;10:1212. [PMID: 31988390 DOI: 10.1038/s41598-020-58290-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 18.0] [Reference Citation Analysis]
314 McCarter C, Kletter D, Tang H, Partyka K, Ma Y, Singh S, Yadav J, Bern M, Haab BB. Prediction of glycan motifs using quantitative analysis of multi-lectin binding: Motifs on MUC1 produced by cultured pancreatic cancer cells. Proteomics Clin Appl 2013;7:632-41. [PMID: 23956151 DOI: 10.1002/prca.201300069] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
315 Kalisz M, Bernardo E, Beucher A, Maestro MA, Del Pozo N, Millán I, Haeberle L, Schlensog M, Safi SA, Knoefel WT, Grau V, de Vas M, Shpargel KB, Vaquero E, Magnuson T, Ortega S, Esposito I, Real FX, Ferrer J. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer. EMBO J 2020;39:e102808. [PMID: 32154941 DOI: 10.15252/embj.2019102808] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
316 Recouvreux MV, Moldenhauer MR, Galenkamp KMO, Jung M, James B, Zhang Y, Lowy A, Bagchi A, Commisso C. Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. J Exp Med 2020;217:e20200388. [PMID: 32510550 DOI: 10.1084/jem.20200388] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
317 Storz P, Crawford HC. Carcinogenesis of Pancreatic Ductal Adenocarcinoma. Gastroenterology 2020;158:2072-81. [PMID: 32199881 DOI: 10.1053/j.gastro.2020.02.059] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
318 Poh AR, Ernst M. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges. Cancers (Basel) 2021;13:2860. [PMID: 34201127 DOI: 10.3390/cancers13122860] [Reference Citation Analysis]
319 Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013;62:751-9. [PMID: 22773551 DOI: 10.1136/gutjnl-2012-302759] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 7.9] [Reference Citation Analysis]
320 Wang Y, Lakoma A, Zogopoulos G. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes (Basel) 2020;11:E1098. [PMID: 32967105 DOI: 10.3390/genes11091098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
321 Yue Y, Song M, Qiao Y, Li P, Yuan Y, Lian J, Wang S, Zhang Y. Gene function analysis and underlying mechanism of esophagus cancer based on microarray gene expression profiling. Oncotarget 2017;8:105222-37. [PMID: 29285246 DOI: 10.18632/oncotarget.22160] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
322 Schofield HK, Zeller J, Espinoza C, Halbrook CJ, Del Vecchio A, Magnuson B, Fabo T, Daylan AEC, Kovalenko I, Lee HJ, Yan W, Feng Y, Karim SA, Kremer DM, Kumar-Sinha C, Lyssiotis CA, Ljungman M, Morton JP, Galbán S, Fearon ER, Pasca di Magliano M. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. JCI Insight 2018;3:97422. [PMID: 29367463 DOI: 10.1172/jci.insight.97422] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
323 Ayres Pereira M, Chio IIC. Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. Genes (Basel) 2019;11:E6. [PMID: 31861620 DOI: 10.3390/genes11010006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
324 Somerville TDD, Xu Y, Wu XS, Maia-Silva D, Hur SK, de Almeida LMN, Preall JB, Koo PK, Vakoc CR. ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer. Proc Natl Acad Sci U S A 2020;117:11471-82. [PMID: 32385160 DOI: 10.1073/pnas.1921484117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
325 Jeon SY, Kim WK, Kim H. [Molecular Classification of Colorectal Cancers and Clinical Application]. Korean J Gastroenterol 2016;68:297-302. [PMID: 28025472 DOI: 10.4166/kjg.2016.68.6.297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
326 Guler GD, Ning Y, Ku CJ, Phillips T, McCarthy E, Ellison CK, Bergamaschi A, Collin F, Lloyd P, Scott A, Antoine M, Wang W, Chau K, Ashworth A, Quake SR, Levy S. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun 2020;11:5270. [PMID: 33077732 DOI: 10.1038/s41467-020-18965-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
327 Feldmann K, Maurer C, Peschke K, Teller S, Schuck K, Steiger K, Engleitner T, Öllinger R, Nomura A, Wirges N, Papargyriou A, Jahan Sarker RS, Ranjan RA, Dantes Z, Weichert W, Rustgi AK, Schmid RM, Rad R, Schneider G, Saur D, Reichert M. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Gastroenterology 2021;160:346-361.e24. [PMID: 33007300 DOI: 10.1053/j.gastro.2020.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
328 Teodorczyk M, Kleber S, Wollny D, Sefrin JP, Aykut B, Mateos A, Herhaus P, Sancho-Martinez I, Hill O, Gieffers C, Sykora J, Weichert W, Eisen C, Trumpp A, Sprick MR, Bergmann F, Welsch T, Martin-Villalba A. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death Differ 2015;22:1192-202. [PMID: 25613377 DOI: 10.1038/cdd.2014.217] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
329 Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, Boudreau A, Mroue R, Corson L, O'Brien T, Qing J, Sampath D, Merchant M, Yauch R, Manning G, Settleman J, Hatzivassiliou G, Evangelista M. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci USA. 2015;112:E4410-E4417. [PMID: 26216984 DOI: 10.1073/pnas.1501605112] [Cited by in Crossref: 168] [Cited by in F6Publishing: 137] [Article Influence: 28.0] [Reference Citation Analysis]
330 Bernard B, Rajamanickam V, Dubay C, Piening B, Alonso E, Jutric Z, Tang E, Newell P, Hansen P, Medler T, Gunderson A, Young K, Bifulco C, Pucliowska J, Crittenden MR, Gough MJ. Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer. PLoS One 2020;15:e0238380. [PMID: 32866185 DOI: 10.1371/journal.pone.0238380] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
331 Zhang S, Jing Y, Zhang M, Zhang Z, Ma P, Peng H, Shi K, Gao WQ, Zhuang G. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci Rep 2015;5:16066. [PMID: 26530441 DOI: 10.1038/srep16066] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
332 Knoche SM, Larson AC, Sliker BH, Poelaert BJ, Solheim JC. The role of tumor heterogeneity in immune-tumor interactions. Cancer Metastasis Rev 2021;40:377-89. [PMID: 33682030 DOI: 10.1007/s10555-021-09957-3] [Reference Citation Analysis]
333 Karandish F, Mallik S. Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomark Cancer 2016;8:27-35. [PMID: 27147897 DOI: 10.4137/BiC.s34414] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
334 Chang ST, Jeffrey RB, Patel BN, Dimaio MA, Rosenberg J, Willmann JK, Olcott EW. Preoperative Multidetector CT Diagnosis of Extrapancreatic Perineural or Duodenal Invasion Is Associated with Reduced Postoperative Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Preliminary Experience and Implications for Patient Care. Radiology 2016;281:816-25. [DOI: 10.1148/radiol.2016152790] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 7.6] [Reference Citation Analysis]
335 Kuhlmann L, Cummins E, Samudio I, Kislinger T. Cell-surface proteomics for the identification of novel therapeutic targets in cancer. Expert Review of Proteomics 2018;15:259-75. [DOI: 10.1080/14789450.2018.1429924] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
336 Mahadevan KK, Arora KS, Amzallag A, Williams E, Kulkarni AS, Fernandez-Del Castillo C, Lillemoe KD, Bardeesy N, Hong TS, Ferrone CR, Ting DT, Deshpande V. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Mod Pathol 2019;32:844-54. [PMID: 30683911 DOI: 10.1038/s41379-018-0196-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
337 de Santiago I, Yau C, Heij L, Middleton MR, Markowetz F, Grabsch HI, Dustin ML, Sivakumar S. Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes. Int J Cancer 2019;145:1125-37. [PMID: 30720864 DOI: 10.1002/ijc.32186] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
338 Creeden JF, Alganem K, Imami AS, Brunicardi FC, Liu SH, Shukla R, Tomar T, Naji F, McCullumsmith RE. Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases. Int J Mol Sci 2020;21:E8679. [PMID: 33213062 DOI: 10.3390/ijms21228679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
339 De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Bossi P, Locati L, Licitra L, Canevari S. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. Oncotarget 2015;6:9627-42. [PMID: 25821127 DOI: 10.18632/oncotarget.3301] [Cited by in Crossref: 76] [Cited by in F6Publishing: 60] [Article Influence: 15.2] [Reference Citation Analysis]
340 Bowers JS, Bailey SR, Rubinstein MP, Paulos CM, Camp ER. Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. Oncol Rev 2019;13:430. [PMID: 31456872 DOI: 10.4081/oncol.2019.430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
341 Haeberle L, Steiger K, Schlitter AM, Safi SA, Knoefel WT, Erkan M, Esposito I. Stromal heterogeneity in pancreatic cancer and chronic pancreatitis. Pancreatology; Epub ahead of print: May 12, 2018. . [PMID: 29778400 DOI: 10.1016/j.pan.2018.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
342 Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16:207-220. [PMID: 30718832 DOI: 10.1038/s41575-019-0109-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 141] [Article Influence: 102.0] [Reference Citation Analysis]
343 Hayashi A, Fan J, Chen R, Ho Y, Makohon-moore AP, Lecomte N, Zhong Y, Hong J, Huang J, Sakamoto H, Attiyeh MA, Kohutek ZA, Zhang L, Boumiza A, Kappagantula R, Baez P, Bai J, Lisi M, Chadalavada K, Melchor JP, Wong W, Nanjangud GJ, Basturk O, O’reilly EM, Klimstra DS, Hruban RH, Wood LD, Overholtzer M, Iacobuzio-donahue CA. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nat Cancer 2020;1:59-74. [DOI: 10.1038/s43018-019-0010-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 9] [Article Influence: 46.0] [Reference Citation Analysis]
344 Zhang Y, Zhu L, Wang X. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma. Genes (Basel) 2020;11:E155. [PMID: 32024063 DOI: 10.3390/genes11020155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
345 Argentiero A, Calabrese A, Sciacovelli AM, Delcuratolo S, Solimando AG, Brunetti O. Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. Can J Gastroenterol Hepatol 2020;2020:8679751. [PMID: 33102398 DOI: 10.1155/2020/8679751] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Cheung WK, Zhao M, Liu Z, Stevens LE, Cao PD, Fang JE, Westbrook TF, Nguyen DX. Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis. Cancer Cell 2013;23:725-38. [PMID: 23707782 DOI: 10.1016/j.ccr.2013.04.009] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 10.9] [Reference Citation Analysis]
347 Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013;12:2213-2225. [PMID: 23918833 DOI: 10.1158/1535-7163.mct-13-0104] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
348 Drosos Y, Escobar D, Chiang MY, Roys K, Valentine V, Valentine MB, Rehg JE, Sahai V, Begley LA, Ye J, Paul L, McKinnon PJ, Sosa-Pineda B. ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer. Sci Rep 2017;7:11144. [PMID: 28894253 DOI: 10.1038/s41598-017-11661-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
349 Arnes L, Liu Z, Wang J, Maurer C, Sagalovskiy I, Sanchez-Martin M, Bommakanti N, Garofalo DC, Balderes DA, Sussel L, Olive KP, Rabadan R. Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Gut 2019;68:499-511. [PMID: 29440233 DOI: 10.1136/gutjnl-2017-314353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
350 Kim S, Kang M, Lee S, Bae S, Han S, Jang JY, Park T. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer. Biomed Eng Online 2014;13 Suppl 2:S5. [PMID: 25560450 DOI: 10.1186/1475-925X-13-S2-S5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
351 Slee RB, Grimes BR, Bansal R, Gore J, Blackburn C, Brown L, Gasaway R, Jeong J, Victorino J, March KL. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Mol Cancer Ther. 2014;13:307-315. [PMID: 24282275 DOI: 10.1158/1535-7163.mct-13-0324] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
352 Tekin C, Shi K, Daalhuisen JB, Ten Brink MS, Bijlsma MF, Spek CA. PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. Oncotarget 2018;9:32010-23. [PMID: 30174793 DOI: 10.18632/oncotarget.25880] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
353 Xu Y, Liu J, Nipper M, Wang P. Ductal vs. acinar? Recent insights into identifying cell lineage of pancreatic ductal adenocarcinoma. Ann Pancreat Cancer 2019;2:11. [PMID: 31528855 DOI: 10.21037/apc.2019.06.03] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
354 Adam RS, Blomberg I, Ten Hoorn S, Bijlsma MF, Vermeulen L. The recurring features of molecular subtypes in distinct gastrointestinal malignancies-A systematic review. Crit Rev Oncol Hematol 2021;164:103428. [PMID: 34284100 DOI: 10.1016/j.critrevonc.2021.103428] [Reference Citation Analysis]
355 Roy N, Malik S, Villanueva KE, Urano A, Lu X, Von Figura G, Seeley ES, Dawson DW, Collisson EA, Hebrok M. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Genes Dev 2015;29:658-71. [PMID: 25792600 DOI: 10.1101/gad.256628.114] [Cited by in Crossref: 93] [Cited by in F6Publishing: 77] [Article Influence: 15.5] [Reference Citation Analysis]
356 [DOI: 10.1101/2020.08.25.256214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
357 Liu S, Ren J, Ten Dijke P. Targeting TGFβ signal transduction for cancer therapy. Signal Transduct Target Ther 2021;6:8. [PMID: 33414388 DOI: 10.1038/s41392-020-00436-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
358 Wolfe AR, Williams TM. Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. Ann Pancreat Cancer 2018;1:26. [PMID: 32656528 DOI: 10.21037/apc.2018.08.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
359 Swayden M, Iovanna J, Soubeyran P. Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. Heliyon 2018;4:e01055. [PMID: 30582059 DOI: 10.1016/j.heliyon.2018.e01055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
360 Yu Y, Yang G, Huang H, Fu Z, Cao Z, Zheng L, You L, Zhang T. Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. J Exp Clin Cancer Res 2021;40:8. [PMID: 33402215 DOI: 10.1186/s13046-020-01787-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
361 Veenstra VL, Garcia-Garijo A, van Laarhoven HW, Bijlsma MF. Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. Cancers (Basel) 2018;10:E34. [PMID: 29382042 DOI: 10.3390/cancers10020034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
362 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
363 Miura K, Kimura K, Amano R, Yamazoe S, Ohira G, Murata A, Nishio K, Hasegawa T, Yashiro M, Nakata B, Ohira M, Hirakawa K. Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2. BMC Cancer 2016;16:268. [PMID: 27067801 DOI: 10.1186/s12885-016-2297-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
364 Monkman JH, Thompson EW, Nagaraj SH. Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease. Cancers (Basel) 2019;11:E1745. [PMID: 31703358 DOI: 10.3390/cancers11111745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
365 Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A, Jacks T. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun 2017;8:1090. [PMID: 29061961 DOI: 10.1038/s41467-017-00942-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 17.5] [Reference Citation Analysis]
366 Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ. Metastatic progression is associated with dynamic changes in the local microenvironment. Nat Commun 2016;7:12819. [PMID: 27628423 DOI: 10.1038/ncomms12819] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 14.2] [Reference Citation Analysis]
367 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
368 Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther 2019;12:3387-400. [PMID: 31118690 DOI: 10.2147/OTT.S176700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
369 Lee HS, Kim E, Lee J, Park SJ, Hwang HK, Park CH, Jo SY, Kang CM, Hong SM, Kang H, Jo JH, Cho IR, Chung MJ, Park JY, Park SW, Song SY, Han JM, Kim S, Bang S. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. EBioMedicine 2021;65:103218. [PMID: 33639403 DOI: 10.1016/j.ebiom.2021.103218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
370 Jiang Z, White RA, Wang TC. Adult Pancreatic Acinar Progenitor-like Populations in Regeneration and Cancer. Trends Mol Med 2020;26:758-67. [PMID: 32362534 DOI: 10.1016/j.molmed.2020.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
371 Tarasiuk A, Mackiewicz T, Małecka-Panas E, Fichna J. Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool? Cancer Biol Ther 2021;22:347-56. [PMID: 34224317 DOI: 10.1080/15384047.2021.1941584] [Reference Citation Analysis]
372 Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 2018;8:1112-29. [PMID: 29853643 DOI: 10.1158/2159-8290.CD-18-0349] [Cited by in Crossref: 299] [Cited by in F6Publishing: 164] [Article Influence: 99.7] [Reference Citation Analysis]
373 Komo T, Kohashi T, Nakashima A, Ohmori I, Hihara J, Mukaida H, Kaneko M, Hirabayashi N. Mixed adenoneuroendocrine carcinoma of the distal bile duct: A case report. Int J Surg Case Rep 2017;39:203-7. [PMID: 28854410 DOI: 10.1016/j.ijscr.2017.08.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
374 Arpa G, Grillo F, Giuffrida P, Nesi G, Klersy C, Mescoli C, Lenti MV, Lobascio G, Martino M, Latella G, Malvi D, Macciomei MC, Fociani P, Villanacci V, Rizzo A, Ferrero S, Sessa F, Orlandi A, Monteleone G, Biancone L, Cantoro L, Tonelli F, Ciardi A, Poggioli G, Rizzello F, Ardizzone S, Sampietro G, Solina G, Oreggia B, Papi C, D’incà R, Vecchi M, Caprioli F, Caronna R, D’errico A, Fiocca R, Rugge M, Corazza GR, Luinetti O, Paulli M, Solcia E, Di Sabatino A, Vanoli A. Separation of Low- Versus High-grade Crohn’s Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis. Journal of Crohn's and Colitis 2020;14:295-302. [DOI: 10.1093/ecco-jcc/jjz140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
375 Nikolova O, Moser R, Kemp C, Gönen M, Margolin AA. Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer studies. Bioinformatics 2017;33:1362-9. [PMID: 28082455 DOI: 10.1093/bioinformatics/btw836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
376 Feuerecker B, Biechl P, Veltkamp C, Saur D, Eisenreich W. Metabolic Response of Pancreatic Carcinoma Cells under Treatment with Dichloroacetate. Metabolites 2021;11:350. [PMID: 34070873 DOI: 10.3390/metabo11060350] [Reference Citation Analysis]
377 Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3641-8. [PMID: 32234757 DOI: 10.1158/1078-0432.CCR-19-4044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
378 Alam MS, Gaida MM, Bergmann F, Lasitschka F, Giese T, Giese NA, Hackert T, Hinz U, Hussain SP, Kozlov SV, Ashwell JD. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. Nat Med. 2015;21:1337-1343. [PMID: 26479921 DOI: 10.1038/nm.3957] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
379 Montaner J, Ramiro L, Simats A, Tiedt S, Makris K, Jickling GC, Debette S, Sanchez JC, Bustamante A. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nat Rev Neurol 2020;16:247-64. [PMID: 32322099 DOI: 10.1038/s41582-020-0350-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 31.0] [Reference Citation Analysis]
380 Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One. 2012;7:e31507. [PMID: 22363658 DOI: 10.1371/journal.pone.0031507] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 12.3] [Reference Citation Analysis]
381 Reyland ME, Jones DN. Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease. Pharmacol Ther 2016;165:1-13. [PMID: 27179744 DOI: 10.1016/j.pharmthera.2016.05.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
382 Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, Patel SG, Wu N, Hindoyan A, Farrell JJ, Li X, Dawson DW, Wu H. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012;18:1352-63. [PMID: 22261810 DOI: 10.1158/1078-0432.CCR-11-1539] [Cited by in Crossref: 131] [Cited by in F6Publishing: 86] [Article Influence: 14.6] [Reference Citation Analysis]
383 Van den Broeck A, Vankelecom H, Van Eijsden R, Govaere O, Topal B. Molecular markers associated with outcome and metastasis in human pancreatic cancer. J Exp Clin Cancer Res 2012;31:68. [PMID: 22925330 DOI: 10.1186/1756-9966-31-68] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
384 Frappart PO, Hofmann TG. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine. Cancers (Basel) 2020;12:E2750. [PMID: 32987786 DOI: 10.3390/cancers12102750] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
385 Bolm L, Zghurskyi P, Lapshyn H, Petrova E, Zemskov S, Vashist YK, Deichmann S, Honselmann KC, Bronsert P, Keck T, Wellner UF. Alignment of stroma fibers, microvessel density and immune cell populations determine overall survival in pancreatic cancer-An analysis of stromal morphology. PLoS One 2020;15:e0234568. [PMID: 32658932 DOI: 10.1371/journal.pone.0234568] [Reference Citation Analysis]
386 Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, Scarpa A, Lawlor R, Chelala C, Keyse SM, Biankin A, Morton JP, Evans TJ, Barry ST, Sansom OJ, Kocher HM, Marshall JF. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. J Pathol 2019;249:332-42. [PMID: 31259422 DOI: 10.1002/path.5320] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
387 Lenzo FL, Kato S, Pabla S, DePietro P, Nesline MK, Conroy JM, Burgher B, Glenn ST, Kuvshinoff B, Kurzrock R, Morrison C. Immune profiling and immunotherapeutic targets in pancreatic cancer. Ann Transl Med 2021;9:119. [PMID: 33569421 DOI: 10.21037/atm-20-1076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
388 Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut 2019;68:159-71. [PMID: 30177543 DOI: 10.1136/gutjnl-2018-316451] [Cited by in Crossref: 104] [Cited by in F6Publishing: 86] [Article Influence: 34.7] [Reference Citation Analysis]
389 Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, Chen W, Liang T. Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget 2018;9:26900-33. [PMID: 29928492 DOI: 10.18632/oncotarget.24809] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
390 Adams CR, Htwe HH, Marsh T, Wang AL, Montoya ML, Subbaraj L, Tward AD, Bardeesy N, Perera RM. Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer. Elife 2019;8:e45313. [PMID: 31134896 DOI: 10.7554/eLife.45313] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 14.5] [Reference Citation Analysis]
391 Golan T, Atias D, Stossel C, Raitses-Gurevich M. Patient-derived xenograft models of BRCA-associated pancreatic cancers. Adv Drug Deliv Rev 2021;171:257-65. [PMID: 33617901 DOI: 10.1016/j.addr.2021.02.010] [Reference Citation Analysis]
392 Neuzillet C, Tijeras-Raballand A, Ragulan C, Cros J, Patil Y, Martinet M, Erkan M, Kleeff J, Wilson J, Apte M, Tosolini M, Wilson AS, Delvecchio FR, Bousquet C, Paradis V, Hammel P, Sadanandam A, Kocher HM. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. J Pathol. 2019;248:51-65. [PMID: 30575030 DOI: 10.1002/path.5224] [Cited by in Crossref: 96] [Cited by in F6Publishing: 80] [Article Influence: 48.0] [Reference Citation Analysis]
393 Zhou B, Irwanto A, Guo Y, Bei J, Wu Q, Chen G, Zhang T, Lei J, Feng Q, Chen L, Liu J, Zhao Y. Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma. Cancer Biology & Therapy 2014;13:871-9. [DOI: 10.4161/cbt.20839] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
394 Bednar F, Simeone DM. Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol. 2011;46:1345-1352. [PMID: 22048257 DOI: 10.1007/s00535-011-0494-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
395 Zhao Q, Sun Y, Liu Z, Zhang H, Li X, Zhu K, Liu Z, Ren J, Zuo Z. CrossICC: iterative consensus clustering of cross-platform gene expression data without adjusting batch effect. Briefings in Bioinformatics 2020;21:1818-24. [DOI: 10.1093/bib/bbz116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
396 Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci USA. 2011;108:E1275-E1284. [PMID: 22084065 DOI: 10.1073/pnas.1111079108] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
397 Gysin S, Paquette J, McMahon M. Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. Mol Cancer Res 2012;10:1607-19. [PMID: 22833572 DOI: 10.1158/1541-7786.MCR-12-0188] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
398 Jin UH, Kim SB, Safe S. Omeprazole Inhibits Pancreatic Cancer Cell Invasion through a Nongenomic Aryl Hydrocarbon Receptor Pathway. Chem Res Toxicol 2015;28:907-18. [PMID: 25826687 DOI: 10.1021/tx5005198] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 7.5] [Reference Citation Analysis]
399 Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S, Yamazoe T, Black T, Sahmoud A, Furth EE, Bar-Sagi D, Stanger BZ. EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Dev Cell 2018;45:681-695.e4. [PMID: 29920274 DOI: 10.1016/j.devcel.2018.05.027] [Cited by in Crossref: 219] [Cited by in F6Publishing: 192] [Article Influence: 73.0] [Reference Citation Analysis]
400 Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323-333. [PMID: 23629472 DOI: 10.1038/nrclinonc.2013.66] [Cited by in Crossref: 133] [Cited by in F6Publishing: 114] [Article Influence: 16.6] [Reference Citation Analysis]
401 Sadanandam A, Wullschleger S, Lyssiotis CA, Grötzinger C, Barbi S, Bersani S, Körner J, Wafy I, Mafficini A, Lawlor RT, Simbolo M, Asara JM, Bläker H, Cantley LC, Wiedenmann B, Scarpa A, Hanahan D. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discov 2015;5:1296-313. [PMID: 26446169 DOI: 10.1158/2159-8290.CD-15-0068] [Cited by in Crossref: 87] [Cited by in F6Publishing: 44] [Article Influence: 14.5] [Reference Citation Analysis]
402 O'dwyer PJ. Locally advanced pancreatic cancer: maybe not so local. The Lancet Oncology 2016;17:694-5. [DOI: 10.1016/s1470-2045(16)30119-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
403 Zhang L, Pleskow DK, Turzhitsky V, Yee EU, Berzin TM, Sawhney M, Shinagare S, Vitkin E, Zakharov Y, Khan U, Wang F, Goldsmith JD, Goldberg S, Chuttani R, Itzkan I, Qiu L, Perelman LT. Light scattering spectroscopy identifies the malignant potential of pancreatic cysts during endoscopy. Nat Biomed Eng 2017;1:0040. [PMID: 29057146 DOI: 10.1038/s41551-017-0040] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
404 Weighill D, Ben Guebila M, Glass K, Platig J, Yeh JJ, Quackenbush J. Gene Targeting in Disease Networks. Front Genet 2021;12:649942. [PMID: 33968133 DOI: 10.3389/fgene.2021.649942] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
405 Mallela J, Ravi S, Jean Louis F, Mulaney B, Cheung M, Sree Garapati U, Chinnasamy V, Wang C, Nagaraj S, Mohapatra SS, Mohapatra S. Natriuretic peptide receptor A signaling regulates stem cell recruitment and angiogenesis: a model to study linkage between inflammation and tumorigenesis. Stem Cells 2013;31:1321-9. [PMID: 23533187 DOI: 10.1002/stem.1376] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
406 Singh HM, Leber MF, Bossow S, Engeland CE, Dessila J, Grossardt C, Zaoui K, Bell JC, Jäger D, von Kalle C, Ungerechts G. MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. Mol Ther Oncolytics 2021;21:340-55. [PMID: 34141871 DOI: 10.1016/j.omto.2021.04.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
407 Ferguson MD, Dong L, Wan J, Deneve JL, Dickson PV, Behrman SW, Shibata D, Martin MG, Glazer ES. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence. J Gastrointest Cancer 2019;50:285-91. [PMID: 29427136 DOI: 10.1007/s12029-018-0073-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
408 Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH. Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas. Mol Oncol 2015;9:758-71. [PMID: 25579086 DOI: 10.1016/j.molonc.2014.12.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
409 Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435-444. [PMID: 22733351 DOI: 10.1038/nrgastro.2012.119] [Cited by in Crossref: 139] [Cited by in F6Publishing: 129] [Article Influence: 15.4] [Reference Citation Analysis]
410 Karamitopoulou E. The Tumor Microenvironment of Pancreatic Cancer. Cancers (Basel) 2020;12:E3076. [PMID: 33096881 DOI: 10.3390/cancers12103076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
411 Hass R, von der Ohe J, Ungefroren H. The Intimate Relationship Among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes. Cancers (Basel) 2020;12:E3674. [PMID: 33297508 DOI: 10.3390/cancers12123674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
412 Glaß M, Dorn A, Hüttelmaier S, Haemmerle M, Gutschner T. Comprehensive Analysis of LincRNAs in Classical and Basal-Like Subtypes of Pancreatic Cancer. Cancers (Basel) 2020;12:E2077. [PMID: 32727085 DOI: 10.3390/cancers12082077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
413 Wang P, Zhang C, Li W, Zhai B, Jiang X, Reddy S, Jiang H, Sun X. Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses. Cell Commun Signal 2020;18:34. [PMID: 32122386 DOI: 10.1186/s12964-020-0522-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
414 Connor AA, Gallinger S. Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong? Expert Rev Gastroenterol Hepatol 2017;11:683-94. [PMID: 28460572 DOI: 10.1080/17474124.2017.1324296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
415 Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM). Biochem J 2017;474:3763-5. [PMID: 29109131 DOI: 10.1042/BCJ20170728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
416 Singh K, Pruski M, Bland R, Younes M, Guha S, Thosani N, Maitra A, Cash BD, McAllister F, Logsdon CD, Chang JT, Bailey-Lundberg JM. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Lab Invest 2021;101:177-92. [PMID: 33009500 DOI: 10.1038/s41374-020-00490-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
417 Zhen DB, Coveler A, Zanon S, Reni M, Chiorean EG. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Semin Oncol. 2018;45:107-115. [PMID: 30391013 DOI: 10.1053/j.seminoncol.2018.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
418 Watanabe S, Shimada S, Akiyama Y, Ishikawa Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Int J Cancer 2019;145:192-205. [PMID: 30556125 DOI: 10.1002/ijc.32072] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
419 Witek MA, Aufforth RD, Wang H, Kamande JW, Jackson JM, Pullagurla SR, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, Gehrig PA, Milowsky MI, Perou CM, Soper JT, Whang YE, Yeh JJ, Martin G, Soper SA. Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule. NPJ Precis Oncol 2017;1:24. [PMID: 29657983 DOI: 10.1038/s41698-017-0028-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
420 Yuan C, Rubinson DA, Qian ZR, Wu C, Kraft P, Bao Y, Ogino S, Ng K, Clancy TE, Swanson RS, Gorman MJ, Brais LK, Li T, Stampfer MJ, Hu FB, Giovannucci EL, Kulke MH, Fuchs CS, Wolpin BM. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol 2015;33:29-35. [PMID: 25403204 DOI: 10.1200/JCO.2014.57.5688] [Cited by in Crossref: 51] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
421 Goonesekere NCW, Andersen W, Smith A, Wang X. Identification of genes highly downregulated in pancreatic cancer through a meta-analysis of microarray datasets: implications for discovery of novel tumor-suppressor genes and therapeutic targets. J Cancer Res Clin Oncol 2018;144:309-20. [PMID: 29288362 DOI: 10.1007/s00432-017-2558-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
422 Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JLY, van Dyk D, Fedyshyn B, Luhova M, Brito GC, Vizeacoumar FJ, Vizeacoumar FS, Datti A, Kasimer D, Buzina A, Mero P, Misquitta C, Normand J, Haider M, Ketela T, Wrana JL, Rottapel R, Neel BG, Moffat J. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov 2012;2:172-89. [PMID: 22585861 DOI: 10.1158/2159-8290.CD-11-0224] [Cited by in Crossref: 212] [Cited by in F6Publishing: 138] [Article Influence: 21.2] [Reference Citation Analysis]
423 Cabarcas SM, Sun L, Mathews L, Thomas S, Zhang X, Farrar WL. The differentiation of pancreatic tumor-initiating cells by vitronectin can be blocked by cilengitide. Pancreas 2013;42:861-70. [PMID: 23462327 DOI: 10.1097/MPA.0b013e318279d568] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
424 Chen L, Xu X, Wen X, Xu S, Wang L, Lu W, Jiang M, Huang J, Yang D, Wang J, Zheng M, Zhou XZ, Lu KP, Liu H. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. Cancer Sci 2019;110:2442-55. [PMID: 31148345 DOI: 10.1111/cas.14085] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
425 Le Large TY, Mato Prado M, Krell J, Bijlsma MF, Meijer LL, Kazemier G, Frampton AE, Giovannetti E. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. Expert Review of Molecular Diagnostics 2016;16:733-6. [DOI: 10.1080/14737159.2016.1175940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
426 Dell'Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, Russano M, Cursano MC, Napolitano A, Zeppola T, Vincenzi B, Tonini G, Santini D. Prognostic and predictive factors in pancreatic cancer. Oncotarget 2020;11:924-41. [PMID: 32206189 DOI: 10.18632/oncotarget.27518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
427 Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res. 2015;21:396-404. [PMID: 25348516 DOI: 10.1158/1078-0432.ccr-14-1591] [Cited by in Crossref: 83] [Cited by in F6Publishing: 56] [Article Influence: 11.9] [Reference Citation Analysis]
428 Lin W, Noel P, Borazanci EH, Lee J, Amini A, Han IW, Heo JS, Jameson GS, Fraser C, Steinbach M, Woo Y, Fong Y, Cridebring D, Von Hoff DD, Park JO, Han H. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome Med 2020;12:80. [PMID: 32988401 DOI: 10.1186/s13073-020-00776-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
429 Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling. Cell 2015;163:1237-51. [PMID: 26590425 DOI: 10.1016/j.cell.2015.10.041] [Cited by in Crossref: 130] [Cited by in F6Publishing: 113] [Article Influence: 26.0] [Reference Citation Analysis]
430 Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Öllinger R, Zwiebel M, Strong A, Yen HY, Banerjee R, Louzada S, Fu B, Seidler B, Götzfried J, Schuck K, Hassan Z, Arbeiter A, Schönhuber N, Klein S, Veltkamp C, Friedrich M, Rad L, Barenboim M, Ziegenhain C, Hess J, Dovey OM, Eser S, Parekh S, Constantino-Casas F, de la Rosa J, Sierra MI, Fraga M, Mayerle J, Klöppel G, Cadiñanos J, Liu P, Vassiliou G, Weichert W, Steiger K, Enard W, Schmid RM, Yang F, Unger K, Schneider G, Varela I, Bradley A, Saur D, Rad R. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 2018;554:62-8. [PMID: 29364867 DOI: 10.1038/nature25459] [Cited by in Crossref: 164] [Cited by in F6Publishing: 125] [Article Influence: 54.7] [Reference Citation Analysis]
431 Rasmussen LG, Verbeke CS, Sørensen MD, Pfeiffer P, Tan Q, Mortensen MB, Fristrup C, Detlefsen S. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. Pancreatology 2021;21:530-43. [PMID: 33637450 DOI: 10.1016/j.pan.2021.01.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
432 Saponara E, Visentin M, Baschieri F, Seleznik G, Martinelli P, Esposito I, Buschmann J, Chen R, Parrotta R, Borgeaud N, Bombardo M, Malagola E, Caflisch A, Farhan H, Graf R, Sonda S. Serotonin uptake is required for Rac1 activation in Kras-induced acinar-to-ductal metaplasia in the pancreas. J Pathol 2018;246:352-65. [PMID: 30058725 DOI: 10.1002/path.5147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
433 Ansari D, Andersson R. Pancreatic ductal adenocarcinoma: is a cure possible? Future Oncol. 2017;13:863-865. [PMID: 28266248 DOI: 10.2217/fon-2016-0571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
434 Hegde S. Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine. Indian J Surg Oncol 2021;12:118-27. [PMID: 33994737 DOI: 10.1007/s13193-020-01192-6] [Reference Citation Analysis]
435 Halbrook CJ, Lyssiotis CA. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. Cancer Cell. 2017;31:5-19. [PMID: 28073003 DOI: 10.1016/j.ccell.2016.12.006] [Cited by in Crossref: 158] [Cited by in F6Publishing: 126] [Article Influence: 39.5] [Reference Citation Analysis]
436 Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, Petricoin EF 3rd. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 2020;21:508-18. [PMID: 32135080 DOI: 10.1016/S1470-2045(20)30074-7] [Cited by in Crossref: 83] [Cited by in F6Publishing: 49] [Article Influence: 83.0] [Reference Citation Analysis]
437 Cardone RA, Greco MR, Zeeberg K, Zaccagnino A, Saccomano M, Bellizzi A, Bruns P, Menga M, Pilarsky C, Schwab A, Alves F, Kalthoff H, Casavola V, Reshkin SJ. A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. Neoplasia 2015;17:155-66. [PMID: 25748234 DOI: 10.1016/j.neo.2014.12.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
438 Thompson ED, Roberts NJ, Wood LD, Eshleman JR, Goggins MG, Kern SE, Klein AP, Hruban RH. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Mod Pathol 2020;33:2544-63. [PMID: 32704031 DOI: 10.1038/s41379-020-0629-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
439 Link JM, Liudahl SM, Betts CB, Sivagnanam S, Leis KR, McDonnell M, Pelz CR, Johnson B, Hamman KJ, Keith D, Sampson JE, Morgan TK, Lopez CD, Coussens LM, Sears RC. Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma. JCO Precis Oncol 2021;5:PO. [PMID: 34036232 DOI: 10.1200/PO.20.00287] [Reference Citation Analysis]
440 Perera RM, Bardeesy N. Ready, set, go: the EGF receptor at the pancreatic cancer starting line. Cancer Cell. 2012;22:281-282. [PMID: 22975369 DOI: 10.1016/j.ccr.2012.08.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
441 O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol 2015;26:1923-9. [PMID: 26091808 DOI: 10.1093/annonc/mdv264] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
442 Ansari D, Torén W, Zhou Q, Hu D, Andersson R. Proteomic and genomic profiling of pancreatic cancer. Cell Biol Toxicol 2019;35:333-43. [PMID: 30771135 DOI: 10.1007/s10565-019-09465-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
443 Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, Sexton KC, Greeno EW, Christein JD, Heslin MJ, Posey JA, Grizzle WE, Vickers SM, Buchsbaum DJ, Cooper SJ, Myers RM. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Mol Oncol. 2016;10:1169-1182. [PMID: 27282075 DOI: 10.1016/j.molonc.2016.05.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
444 Shabaik YH, Millard M, Neamati N. Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cells. PLoS One 2013;8:e54346. [PMID: 23349858 DOI: 10.1371/journal.pone.0054346] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
445 Turkel N, Portela M, Poon C, Li J, Brumby AM, Richardson HE. Cooperation of the BTB-Zinc finger protein, Abrupt, with cytoskeletal regulators in Drosophila epithelial tumorigenesis. Biol Open 2015;4:1024-39. [PMID: 26187947 DOI: 10.1242/bio.012815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
446 Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, Mansour J, Witkiewicz AK. Pancreatic cancer cell lines as patient-derived avatars: Genetic characterisation and functional utility. Gut. 2018;67:508-520. [PMID: 28073890 DOI: 10.1136/gutjnl-2016-313133] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
447 Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, Fletcher-Sananikone E, Lim C, Horwitz GI, Viale A, Pettazzoni P, Sanchez N, Wang H, Protopopov A, Zhang J, Heffernan T, Johnson RL, Chin L, Wang YA, Draetta G, DePinho RA. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014;158:185-197. [PMID: 24954535 DOI: 10.1016/j.cell.2014.06.003] [Cited by in Crossref: 381] [Cited by in F6Publishing: 334] [Article Influence: 54.4] [Reference Citation Analysis]
448 Collins MA, Pasca di Magliano M. Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol. 2013;4:407. [PMID: 24478710 DOI: 10.3389/fphys.2013.00407] [Cited by in Crossref: 38] [Cited by in F6Publishing: 63] [Article Influence: 5.4] [Reference Citation Analysis]
449 Alcalá S, Mayoral-Varo V, Ruiz-Cañas L, López-Gil JC, Heeschen C, Martín-Pérez J, Sainz B Jr. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Int J Mol Sci 2020;21:E7437. [PMID: 33050159 DOI: 10.3390/ijms21207437] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
450 Wolfe AR, Wald P, Webb A, Sebastian N, Walston S, Robb R, Chen W, Vedaie M, Dillhoff M, Frankel WL, Kwon W, Jang JY, Williams TM. A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection. Oncotarget 2020;11:913-23. [PMID: 32206188 DOI: 10.18632/oncotarget.27496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
451 Pihlajoki M, Färkkilä A, Soini T, Heikinheimo M, Wilson DB. GATA factors in endocrine neoplasia. Mol Cell Endocrinol 2016;421:2-17. [PMID: 26027919 DOI: 10.1016/j.mce.2015.05.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
452 Dreyer SB, Pinese M, Jamieson NB, Scarlett CJ, Colvin EK, Pajic M, Johns AL, Humphris JL, Wu J, Cowley MJ, Chou A, Nagrial AM, Chantrill L, Chin VT, Jones MD, Moran-Jones K, Carter CR, Dickson EJ, Samra JS, Merrett ND, Gill AJ, Kench JG, Duthie F, Miller DK, Cooke S, Aust D, Knösel T, Rümmele P, Grützmann R, Pilarsky C, Nguyen NQ, Musgrove EA, Bailey PJ, McKay CJ, Biankin AV, Chang DK; Australian Pancreatic Cancer Genome Initiative., Glasgow Precision Oncology Laboratory. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Ann Surg 2020;272:366-76. [PMID: 32675551 DOI: 10.1097/SLA.0000000000003143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
453 Usón PLS Junior, Tolentino FDS, Santos VM, Rother ET, Maluf FC. The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies. PLoS One 2020;15:e0230060. [PMID: 32130264 DOI: 10.1371/journal.pone.0230060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
454 da Silva-Diz V, Lorenzo-Sanz L, Bernat-Peguera A, Lopez-Cerda M, Muñoz P. Cancer cell plasticity: Impact on tumor progression and therapy response. Semin Cancer Biol 2018;53:48-58. [PMID: 30130663 DOI: 10.1016/j.semcancer.2018.08.009] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 24.7] [Reference Citation Analysis]
455 Sántha P, Lenggenhager D, Finstadsveen A, Dorg L, Tøndel K, Amrutkar M, Gladhaug IP, Verbeke C. Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence. Cancers (Basel) 2021;13:895. [PMID: 33672734 DOI: 10.3390/cancers13040895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
456 Aguirre AJ, Collisson EA. Advances in the Genetics and Biology of Pancreatic Cancer. Cancer J 2017;23:315-20. [PMID: 29189326 DOI: 10.1097/PPO.0000000000000286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
457 Burr R, Gilles C, Thompson EW, Maheswaran S. Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis. Adv Exp Med Biol 2020;1220:11-34. [PMID: 32304077 DOI: 10.1007/978-3-030-35805-1_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
458 Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med 2016;22:497-505. [PMID: 27089513 DOI: 10.1038/nm.4082] [Cited by in Crossref: 287] [Cited by in F6Publishing: 260] [Article Influence: 57.4] [Reference Citation Analysis]
459 Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, Sheinin Y, Rachagani S, Natarajan G, Brand RE, Macha MA, Grandgenett PM, Kaur S, Batra SK. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. EBioMedicine. 2019;42:375-385. [PMID: 30956167 DOI: 10.1016/j.ebiom.2019.03.056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
460 Cancer Genome Atlas Research Network. Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185-203.e13. [PMID: 28810144 DOI: 10.1016/j.ccell.2017.07.007] [Cited by in Crossref: 700] [Cited by in F6Publishing: 534] [Article Influence: 175.0] [Reference Citation Analysis]
461 Chao T, Furth EE, Vonderheide RH. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res 2016;4:968-82. [PMID: 27737879 DOI: 10.1158/2326-6066.CIR-16-0188] [Cited by in Crossref: 99] [Cited by in F6Publishing: 72] [Article Influence: 19.8] [Reference Citation Analysis]
462 Veenstra VL, Damhofer H, Waasdorp C, Steins A, Kocher HM, Medema JP, van Laarhoven HW, Bijlsma MF. Stromal SPOCK1 supports invasive pancreatic cancer growth. Mol Oncol 2017;11:1050-64. [PMID: 28486750 DOI: 10.1002/1878-0261.12073] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
463 Meleady P, Abdul Rahman R, Henry M, Moriarty M, Clynes M. Proteomic analysis of pancreatic ductal adenocarcinoma. Expert Rev Proteomics 2020;17:453-67. [PMID: 32755290 DOI: 10.1080/14789450.2020.1803743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
464 Yang F, Jin C, Subedi S, Lee CL, Wang Q, Jiang Y, Li J, Di Y, Fu D. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat Rev. 2012;38:566-579. [PMID: 22655679 DOI: 10.1016/j.ctrv.2012.02.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 58] [Article Influence: 8.4] [Reference Citation Analysis]
465 Kim S, Lahmy R, Riha C, Yang C, Jakubison BL, van Niekerk J, Staub C, Wu Y, Gates K, Dong DS. The basic helix-loop-helix transcription factor E47 reprograms human pancreatic cancer cells to a quiescent acinar state with reduced tumorigenic potential. Pancreas. 2015;44:718-727. [PMID: 25894862 DOI: 10.1097/mpa.0000000000000328] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
466 Cano CE, Hamidi T, Garcia MN, Grasso D, Loncle C, Garcia S, Calvo E, Lomberk G, Dusetti N, Bartholin L. Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. Gut. 2013;Epub ahead of print. [PMID: 24026351 DOI: 10.1136/gutjnl-2013-305221] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
467 Shi H, Li H, Zhen T, Dong Y, Pei X, Zhang X. hsa_circ_001653 Implicates in the Development of Pancreatic Ductal Adenocarcinoma by Regulating MicroRNA-377-Mediated HOXC6 Axis. Mol Ther Nucleic Acids 2020;20:252-64. [PMID: 32193152 DOI: 10.1016/j.omtn.2019.12.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
468 Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, Wilson G, Grant RC, Merico D, Lungu I, Bartlett JMS, Chadwick D, Liang SB, Eagles J, Mbabaali F, Miller JK, Krzyzanowski P, Armstrong H, Luo X, Jorgensen LGT, Romero JM, Bavi P, Fischer SE, Serra S, Hafezi-Bakhtiari S, Caglar D, Roehrl MHA, Cleary S, Hollingsworth MA, Petersen GM, Thayer S, Law CHL, Nanji S, Golan T, Smith AL, Borgida A, Dodd A, Hedley D, Wouters BG, O'Kane GM, Wilson JM, Zogopoulos G, Notta F, Knox JJ, Gallinger S. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Cancer Cell 2019;35:267-282.e7. [PMID: 30686769 DOI: 10.1016/j.ccell.2018.12.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 29.0] [Reference Citation Analysis]
469 Martinelli P, Cañamero M, del Pozo N, Madriles F, Zapata A, Real FX. Gata6 is required for complete acinar differentiation and maintenance of the exocrine pancreas in adult mice. Gut 2013;62:1481-8. [DOI: 10.1136/gutjnl-2012-303328] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
470 Hu D, Ansari D, Pawłowski K, Zhou Q, Sasor A, Welinder C, Kristl T, Bauden M, Rezeli M, Jiang Y, Marko-Varga G, Andersson R. Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma. Oncotarget 2018;9:9789-807. [PMID: 29515771 DOI: 10.18632/oncotarget.23929] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
471 O'Kane GM, Ladak F, Gallinger S. Advances in the management of pancreatic ductal adenocarcinoma. CMAJ 2021;193:E844-51. [PMID: 34099468 DOI: 10.1503/cmaj.201450] [Reference Citation Analysis]
472 Zhao L, Zhao H, Yan H. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. BMC Cancer 2018;18:603. [PMID: 29843660 DOI: 10.1186/s12885-018-4546-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 10.7] [Reference Citation Analysis]
473 Sasaki N, Toyoda M, Ishiwata T. Gangliosides as Signaling Regulators in Cancer. Int J Mol Sci 2021;22:5076. [PMID: 34064863 DOI: 10.3390/ijms22105076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
474 Coleman O, Henry M, O'Neill F, Roche S, Swan N, Geoghegan J, Conlon K, McVey G, Moriarty M, Meleady P, Clynes M. Proteomic Analysis of Cell Lines and Primary Tumors in Pancreatic Cancer Identifies Proteins Expressed Only In Vitro and Only In Vivo. Pancreas 2020;49:1109-16. [PMID: 32833945 DOI: 10.1097/MPA.0000000000001633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
475 [DOI: 10.1101/2020.07.28.225813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
476 Varga J, Greten FR. Cell plasticity in epithelial homeostasis and tumorigenesis. Nat Cell Biol. 2017;19:1133-1141. [PMID: 28945230 DOI: 10.1038/ncb3611] [Cited by in Crossref: 114] [Cited by in F6Publishing: 97] [Article Influence: 28.5] [Reference Citation Analysis]
477 Farran B, Nagaraju GP. The dynamic interactions between the stroma, pancreatic stellate cells and pancreatic tumor development: Novel therapeutic targets. Cytokine & Growth Factor Reviews 2019;48:11-23. [DOI: 10.1016/j.cytogfr.2019.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
478 [DOI: 10.1101/198903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
479 Pizzuto MS, Silic-benussi M, Ciminale V, Elderfield RA, Capua I, Barclay WS. An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy. Journal of General Virology 2016;97:2166-79. [DOI: 10.1099/jgv.0.000549] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
480 Previdi MC, Carotenuto P, Zito D, Pandolfo R, Braconi C. Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? Future Oncol 2017;13:443-53. [PMID: 27841659 DOI: 10.2217/fon-2016-0253] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
481 Hidalgo M. New insights into pancreatic cancer biology. Ann Oncol. 2012;23 Suppl 10:x135-x138. [PMID: 22987949 DOI: 10.1093/annonc/mds313] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
482 Peng D, Gleyzer R, Tai WH, Kumar P, Bian Q, Isaacs B, da Rocha EL, Cai S, DiNapoli K, Huang FW, Cahan P. Evaluating the transcriptional fidelity of cancer models. Genome Med 2021;13:73. [PMID: 33926541 DOI: 10.1186/s13073-021-00888-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
483 Ho J, Li X, Zhang L, Liang Y, Hu W, Yau JCW, Chan H, Gin T, Chan MTV, Tse G, Wu WKK. Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset. Semin Cancer Biol 2019;55:70-7. [PMID: 29705685 DOI: 10.1016/j.semcancer.2018.04.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
484 Wang J, He P, Gaida M, Yang S, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis H, Lee D, Weiss JM, Stauffer J, Hanna N, Alexander HR, Hussain SP. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Oncotarget 2016;7:52993-3004. [PMID: 27367029 DOI: 10.18632/oncotarget.10323] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
485 Balak JRA, Juksar J, Carlotti F, Lo Nigro A, de Koning EJP. Organoids from the Human Fetal and Adult Pancreas. Curr Diab Rep 2019;19:160. [PMID: 31828551 DOI: 10.1007/s11892-019-1261-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
486 van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond) 2020;134:2091-115. [PMID: 32808663 DOI: 10.1042/CS20191211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
487 Beg MS, Gupta A, Sher D, Ali S, Khan S, Gao A, Stewart T, Ahn C, Berry J, Mortensen EM. Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis. Am J Clin Oncol. 2018;41:766-771. [PMID: 28079594 DOI: 10.1097/coc.0000000000000359] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
488 Rodríguez Gil Y, Jiménez Sánchez P, Muñoz Velasco R, García García A, Sánchez-Arévalo Lobo VJ. Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic. Int J Mol Sci 2021;22:2077. [PMID: 33669845 DOI: 10.3390/ijms22042077] [Reference Citation Analysis]
489 Cintas C, Douché T, Therville N, Arcucci S, Ramos-Delgado F, Basset C, Thibault B, Guillermet-Guibert J. Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. Cancers (Basel) 2018;10:E174. [PMID: 29865155 DOI: 10.3390/cancers10060174] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
490 Esposito I, Konukiewitz B, Schlitter AM, Klöppel G. Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments. World J Gastroenterol. 2014;20:13833-13841. [PMID: 25320520 DOI: 10.3748/wjg.v20.i38.13833] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
491 Nahm CB, Turchini J, Jamieson N, Moon E, Sioson L, Itchins M, Arena J, Colvin E, Howell VM, Pavlakis N, Clarke S, Samra JS, Gill AJ, Mittal A. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. Eur J Surg Oncol 2019;45:218-24. [PMID: 30348604 DOI: 10.1016/j.ejso.2018.10.050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
492 Hoyer K, Hablesreiter R, Inoue Y, Yoshida K, Briest F, Christen F, Kakiuchi N, Yoshizato T, Shiozawa Y, Shiraishi Y, Striefler JK, Bischoff S, Lohneis P, Putter H, Blau O, Keilholz U, Bullinger L, Pelzer U, Hummel M, Riess H, Ogawa S, Sinn M, Damm F. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. EBioMedicine 2021;66:103327. [PMID: 33862582 DOI: 10.1016/j.ebiom.2021.103327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
493 Kim K, Bolotin E, Theusch E, Huang H, Medina MW, Krauss RM. Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation. Genome Biol 2014;15:460. [PMID: 25316374 DOI: 10.1186/s13059-014-0460-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
494 Ruess DA, Görgülü K, Wörmann SM, Algül H. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs Aging 2017;34:331-57. [PMID: 28349415 DOI: 10.1007/s40266-017-0453-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
495 Thibault B, Ramos-Delgado F, Pons-Tostivint E, Therville N, Cintas C, Arcucci S, Cassant-Sourdy S, Reyes-Castellanos G, Tosolini M, Villard AV, Cayron C, Baer R, Bertrand-Michel J, Pagan D, Ferreira Da Mota D, Yan H, Falcomatà C, Muscari F, Bournet B, Delord JP, Aksoy E, Carrier A, Cordelier P, Saur D, Basset C, Guillermet-Guibert J. Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component. EMBO Mol Med 2021;13:e13502. [PMID: 34033220 DOI: 10.15252/emmm.202013502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
496 Javle M, Golan T, Maitra A. Changing the course of pancreatic cancer--Focus on recent translational advances. Cancer Treat Rev 2016;44:17-25. [PMID: 26924195 DOI: 10.1016/j.ctrv.2016.01.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
497 Nicolle R, Blum Y, Marisa L, Loncle C, Gayet O, Moutardier V, Turrini O, Giovannini M, Bian B, Bigonnet M, Rubis M, Elarouci N, Armenoult L, Ayadi M, Duconseil P, Gasmi M, Ouaissi M, Maignan A, Lomberk G, Boher JM, Ewald J, Bories E, Garnier J, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Grandval P, Barraud-Blanc M, Norguet E, Gilabert M, Delpero JR, Roques J, Calvo E, Guillaumond F, Vasseur S, Urrutia R, de Reyniès A, Dusetti N, Iovanna J. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Cell Rep 2017;21:2458-70. [PMID: 29186684 DOI: 10.1016/j.celrep.2017.11.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 25.3] [Reference Citation Analysis]
498 Donahue TR, Dawson DW. Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. Trends Endocrinol Metab 2016;27:770-81. [PMID: 27461042 DOI: 10.1016/j.tem.2016.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
499 Abbassi R, Schmid RM. Evolving Treatment Paradigms for Pancreatic Cancer. Visc Med 2019;35:362-72. [PMID: 31934585 DOI: 10.1159/000503797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
500 Raman P, Maddipati R, Lim KH, Tozeren A. Pancreatic cancer survival analysis defines a signature that predicts outcome. PLoS One 2018;13:e0201751. [PMID: 30092011 DOI: 10.1371/journal.pone.0201751] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
501 Crottès D, Lin YT, Peters CJ, Gilchrist JM, Wiita AP, Jan YN, Jan LY. TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis. Proc Natl Acad Sci U S A 2019;116:13026-35. [PMID: 31182586 DOI: 10.1073/pnas.1900703116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
502 Blanco VM, Latif T, Chu Z, Qi X. Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol 2015;8:196-203. [PMID: 26055177 DOI: 10.1016/j.tranon.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
503 Gentiluomo M, Puchalt García P, Galeotti AA, Talar-Wojnarowska R, Tjaden C, Tavano F, Strobel O, Kupcinskas J, Neoptolemos J, Hegyi P, Costello E, Pezzilli R, Sperti C, Lawlor RT, Capurso G, Szentesi A, Soucek P, Vodicka P, Lovecek M, Hackert T, Cavestro GM, Milanetto AC, Canzian F, Campa D. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Carcinogenesis 2019;40:544-50. [PMID: 30629142 DOI: 10.1093/carcin/bgz006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
504 Ischenko I, Petrenko O, Hayman MJ. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. Oncotarget 2015;6:15814-27. [PMID: 26158412 DOI: 10.18632/oncotarget.4538] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
505 Westphalen CB, Olive KP. Genetically engineered mouse models of pancreatic cancer. Cancer J 2012;18:502-10. [PMID: 23187836 DOI: 10.1097/PPO.0b013e31827ab4c4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
506 Datta J, Wilson GC, D'Angelica MI, Katz MHG, Maithel SK, Merchant NB, Ahmad SA. A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak. Ann Surg 2021;274:e82-4. [PMID: 33086320 DOI: 10.1097/SLA.0000000000004471] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
507 Young K, Hughes DJ, Cunningham D, Starling N. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Ther Adv Med Oncol. 2018;10:1758835918816281. [PMID: 30574212 DOI: 10.1177/1758835918816281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
508 Oria VO, Bronsert P, Thomsen AR, Föll MC, Zamboglou C, Hannibal L, Behringer S, Biniossek ML, Schreiber C, Grosu AL, Bolm L, Rades D, Keck T, Werner M, Wellner UF, Schilling O. Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. Transl Oncol 2018;11:1307-22. [PMID: 30172883 DOI: 10.1016/j.tranon.2018.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
509 Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2018;24:5883-94. [PMID: 30082477 DOI: 10.1158/1078-0432.CCR-17-3668] [Cited by in Crossref: 40] [Cited by in F6Publishing: 20] [Article Influence: 13.3] [Reference Citation Analysis]
510 Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 2020;73:315-27. [PMID: 32173382 DOI: 10.1016/j.jhep.2020.03.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 29.0] [Reference Citation Analysis]
511 Yamada S, Fuchs BC, Fujii T, Shimoyama Y, Sugimoto H, Nomoto S, Takeda S, Tanabe KK, Kodera Y, Nakao A. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery. 2013;154:946-954. [PMID: 24075276 DOI: 10.1016/j.surg.2013.05.004] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 10.4] [Reference Citation Analysis]
512 Nie S, Qian X, Shi M, Li H, Peng C, Ding X, Zhang S, Zhang B, Xu G, Lv Y, Wang L, Friess H, Kong B, Zou X, Shen S. ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Front Oncol 2020;10:915. [PMID: 32612951 DOI: 10.3389/fonc.2020.00915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
513 Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017;18:E909. [PMID: 28445400 DOI: 10.3390/ijms18050909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
514 Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis 2018;7:87. [PMID: 30442938 DOI: 10.1038/s41389-018-0096-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
515 Minami F, Sasaki N, Shichi Y, Gomi F, Michishita M, Ohkusu-Tsukada K, Toyoda M, Takahashi K, Ishiwata T. Morphofunctional analysis of human pancreatic cancer cell lines in 2- and 3-dimensional cultures. Sci Rep 2021;11:6775. [PMID: 33762591 DOI: 10.1038/s41598-021-86028-1] [Reference Citation Analysis]
516 Rashid NU, Peng XL, Jin C, Moffitt RA, Volmar KE, Belt BA, Panni RZ, Nywening TM, Herrera SG, Moore KJ, Hennessey SG, Morrison AB, Kawalerski R, Nayyar A, Chang AE, Schmidt B, Kim HJ, Linehan DC, Yeh JJ. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Clin Cancer Res 2020;26:82-92. [PMID: 31754050 DOI: 10.1158/1078-0432.CCR-19-1467] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
517 Yin X, Kong L, Liu P. Identification of prognosis-related molecular subgroups based on DNA methylation in pancreatic cancer. Clin Epigenetics 2021;13:109. [PMID: 33980289 DOI: 10.1186/s13148-021-01090-w] [Reference Citation Analysis]
518 Davis HW, Kaynak A, Vallabhapurapu SD, Qi X. Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer. World J Gastrointest Oncol 2021;13:550-9. [PMID: 34163572 DOI: 10.4251/wjgo.v13.i6.550] [Reference Citation Analysis]
519 Fujita Y, Matsuda S, Sasaki Y, Masugi Y, Kitago M, Yagi H, Abe Y, Shinoda M, Tokino T, Sakamoto M, Kitagawa Y. Pathogenesis of multiple pancreatic cancers involves multicentric carcinogenesis and intrapancreatic metastasis. Cancer Sci. 2020;111:739-748. [PMID: 31799787 DOI: 10.1111/cas.14268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
520 Kawalerski RR, Leach SD, Escobar-Hoyos LF. Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies. Oncotarget 2021;12:525-33. [PMID: 33796221 DOI: 10.18632/oncotarget.27901] [Reference Citation Analysis]
521 Berger AK, Singh HM, Werft W, Muckenhuber A, Sprick MR, Trumpp A, Weichert W, Jäger D, Springfeld C. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. Pancreatology 2017;17:629-34. [DOI: 10.1016/j.pan.2017.04.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
522 Buanes TA. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World J Gastroenterol 2016;22:10502-11. [PMID: 28082802 DOI: 10.3748/wjg.v22.i48.10502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
523 Hoover M, Adamian Y, Brown M, Maawy A, Chang A, Lee J, Gharibi A, Katz MH, Fleming J, Hoffman RM, Bouvet M, Doebler R, Kelber JA. A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts. Oncotarget 2017;8:5885-94. [PMID: 27602776 DOI: 10.18632/oncotarget.11809] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
524 Giovannetti E, van der Borden CL, Frampton AE, Ali A, Firuzi O, Peters GJ. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Semin Cancer Biol 2017;44:43-59. [PMID: 28438662 DOI: 10.1016/j.semcancer.2017.04.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 12.5] [Reference Citation Analysis]
525 Guan Y, Yang YJ, Nagarajan P, Ge Y. Transcriptional and signalling regulation of skin epithelial stem cells in homeostasis, wounds and cancer. Exp Dermatol 2021;30:529-45. [PMID: 33249665 DOI: 10.1111/exd.14247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
526 Chen H, Zhu X, Sun R, Ma P, Zhang E, Wang Z, Fan Y, Zhou G, Mao R. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance. Invest New Drugs 2020;38:1707-16. [PMID: 32468271 DOI: 10.1007/s10637-020-00951-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
527 Somerville TD, Biffi G, Daßler-Plenker J, Hur SK, He XY, Vance KE, Miyabayashi K, Xu Y, Maia-Silva D, Klingbeil O, Demerdash OE, Preall JB, Hollingsworth MA, Egeblad M, Tuveson DA, Vakoc CR. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. Elife 2020;9:e53381. [PMID: 32329713 DOI: 10.7554/eLife.53381] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
528 Le Large TY, Mantini G, Meijer LL, Pham TV, Funel N, van Grieken NC, Kok B, Knol J, van Laarhoven HW, Piersma SR, Jimenez CR, Kazemier G, Giovannetti E, Bijlsma MF. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. JCI Insight 2020;5:138290. [PMID: 32634123 DOI: 10.1172/jci.insight.138290] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
529 Pandey R, Zhou M, Islam S, Chen B, Barker NK, Langlais P, Srivastava A, Luo M, Cooke LS, Weterings E, Mahadevan D. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target. Sci Rep. 2019;9:18347. [PMID: 31797958 DOI: 10.1038/s41598-019-54545-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
530 Barnett D, Liu Y, Partyka K, Huang Y, Tang H, Hostetter G, Brand RE, Singhi AD, Drake RR, Haab BB. The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells. Sci Rep. 2017;7:4020. [PMID: 28642461 DOI: 10.1038/s41598-017-04164-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
531 Luo Y, Xin Y, Hochberg E, Joshi R, Uzuner O, Szolovits P. Subgraph augmented non-negative tensor factorization (SANTF) for modeling clinical narrative text. J Am Med Inform Assoc 2015;22:1009-19. [PMID: 25862765 DOI: 10.1093/jamia/ocv016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
532 Roesli C. Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact. Expert Review of Proteomics 2014;12:5-8. [DOI: 10.1586/14789450.2015.983478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
533 Giri B, Sethi V, Dudeja V, Banerjee S, Livingstone A, Saluja A. Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants. Curr Opin Gastroenterol 2017;33:404-10. [PMID: 28682795 DOI: 10.1097/MOG.0000000000000382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
534 Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. J Clin Oncol 2017;35:3330-7. [PMID: 28817370 DOI: 10.1200/JCO.2017.72.6463] [Cited by in Crossref: 124] [Cited by in F6Publishing: 57] [Article Influence: 31.0] [Reference Citation Analysis]
535 Guo JC, Zhang P, Zhou L, You L, Liu QF, Zhang ZG, Sun B, Liang ZY, Lu J, Yuan D, Tan AD, Sun J, Liao Q, Dai MH, Xiao GG, Li S, Zhang TP. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. EBioMedicine 2020;55:102767. [PMID: 32361251 DOI: 10.1016/j.ebiom.2020.102767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
536 Hayashi H, Baba H. Precision surgery with the genetic assessment for operable pancreatic cancer beyond the radiological assessment alone. Hepatobiliary Surg Nutr 2021;10:261-3. [PMID: 33898572 DOI: 10.21037/hbsn-20-820] [Reference Citation Analysis]
537 Song W, He X, Gong P, Yang Y, Huang S, Zeng Y, Wei L, Zhang J. Glycolysis-Related Gene Expression Profiling Screen for Prognostic Risk Signature of Pancreatic Ductal Adenocarcinoma. Front Genet 2021;12:639246. [PMID: 34249078 DOI: 10.3389/fgene.2021.639246] [Reference Citation Analysis]
538 Hoffmann AC, Goekkurt E, Danenberg PV, Lehmann S, Ehninger G, Aust DE, Stoehlmacher-Williams J. EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma. PLoS One 2013;8:e64186. [PMID: 23704979 DOI: 10.1371/journal.pone.0064186] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
539 Sivakumar S, de Santiago I, Chlon L, Markowetz F. Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis. PLoS Med 2017;14:e1002223. [PMID: 28141826 DOI: 10.1371/journal.pmed.1002223] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
540 Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, von Strandmann EP, Slater EP, Bartsch JW, Bauer C, Lauth M. The Immune Microenvironment in Pancreatic Cancer. Int J Mol Sci 2020;21:E7307. [PMID: 33022971 DOI: 10.3390/ijms21197307] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 22.0] [Reference Citation Analysis]
541 Kuhlmann L, Nadler WM, Kerner A, Hanke SA, Noll EM, Eisen C, Espinet E, Vogel V, Trumpp A, Sprick MR, Roesli CP. Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Pancreas 2017;46:311-22. [DOI: 10.1097/mpa.0000000000000743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
542 Masin M, Vazquez J, Rossi S, Groeneveld S, Samson N, Schwalie PC, Deplancke B, Frawley LE, Gouttenoire J, Moradpour D. GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. Cancer Metab. 2014;2:11. [PMID: 25097756 DOI: 10.1186/2049-3002-2-11] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
543 Bear AS, Vonderheide RH, O'Hara MH. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell 2020;38:788-802. [PMID: 32946773 DOI: 10.1016/j.ccell.2020.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
544 Luo Y, Mao C, Yang Y, Wang F, Ahmad FS, Arnett D, Irvin MR, Shah SJ. Integrating hypertension phenotype and genotype with hybrid non-negative matrix factorization. Bioinformatics 2019;35:1395-403. [PMID: 30239588 DOI: 10.1093/bioinformatics/bty804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
545 Seppälä TT, Burkhart RA. Can Pancreatic Organoids Help in the Treatment of Pancreatic Cancer? Adv Surg 2021;55:215-29. [PMID: 34389093 DOI: 10.1016/j.yasu.2021.05.015] [Reference Citation Analysis]
546 Striefler JK, Riess H, Lohneis P, Bischoff S, Kurreck A, Modest DP, Bahra M, Oettle H, Sinn M, Bläker H, Denkert C, Stintzing S, Sinn BV, Pelzer U. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Front Oncol 2021;11:670396. [PMID: 34386419 DOI: 10.3389/fonc.2021.670396] [Reference Citation Analysis]
547 Xu X, Yang Y, Mo X, Wei J, Zhang X, You Q. Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway. European Journal of Medicinal Chemistry 2017;137:45-62. [DOI: 10.1016/j.ejmech.2017.05.042] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
548 Waldron L, Ogino S, Hoshida Y, Shima K, McCart Reed AE, Simpson PT, Baba Y, Nosho K, Segata N, Vargas AC, Cummings MC, Lakhani SR, Kirkner GJ, Giovannucci E, Quackenbush J, Golub TR, Fuchs CS, Parmigiani G, Huttenhower C. Expression profiling of archival tumors for long-term health studies. Clin Cancer Res 2012;18:6136-46. [PMID: 23136189 DOI: 10.1158/1078-0432.CCR-12-1915] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
549 Zaccari P, Cardinale V, Severi C, Pedica F, Carpino G, Gaudio E, Doglioni C, Petrone MC, Alvaro D, Arcidiacono PG, Capurso G. Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas. World J Gastroenterol. 2019;25:4343-4359. [PMID: 31496617 DOI: 10.3748/wjg.v25.i31.4343] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
550 Camolotto SA, Belova VK, Torre-Healy L, Vahrenkamp JM, Berrett KC, Conway H, Shea J, Stubben C, Moffitt R, Gertz J, Snyder EL. Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4. Gut 2021;70:900-14. [PMID: 32826305 DOI: 10.1136/gutjnl-2020-321316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
551 Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A, Shen MM. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol. 2013;15:274-283. [PMID: 23434823 DOI: 10.1038/ncb2697] [Cited by in Crossref: 200] [Cited by in F6Publishing: 176] [Article Influence: 25.0] [Reference Citation Analysis]
552 Bijlsma MF, van Laarhoven HW. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer Metastasis Rev 2015;34:97-114. [PMID: 25566685 DOI: 10.1007/s10555-014-9541-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
553 Kristensen VN, Lingjærde OC, Russnes HG, Vollan HKM, Frigessi A, Børresen-dale A. Principles and methods of integrative genomic analyses in cancer. Nat Rev Cancer 2014;14:299-313. [DOI: 10.1038/nrc3721] [Cited by in Crossref: 243] [Cited by in F6Publishing: 162] [Article Influence: 34.7] [Reference Citation Analysis]
554 Quadri HS, Aiken TJ, Allgaeuer M, Moravec R, Altekruse S, Hussain SP, Miettinen MM, Hewitt SM, Rudloff U. Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer. BMC Cancer 2017;17:495. [PMID: 28732488 DOI: 10.1186/s12885-017-3481-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
555 Singh RR, O'Reilly EM. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Drugs 2020;80:647-69. [PMID: 32306207 DOI: 10.1007/s40265-020-01304-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
556 Pan CH, Otsuka Y, Sridharan B, Woo M, Leiton CV, Babu S, Torrente Gonçalves M, Kawalerski RR, K Bai JD, Chang DK, Biankin AV, Scampavia L, Spicer T, Escobar-Hoyos LF, Shroyer KR. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Mol Oncol 2020;14:1800-16. [PMID: 32533886 DOI: 10.1002/1878-0261.12743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
557 Ma W, Li T, Wu S, Li J, Wang X, Li H. LOX and ACSL5 as potential relapse markers for pancreatic cancer patients. Cancer Biol Ther 2019;20:787-98. [PMID: 30712446 DOI: 10.1080/15384047.2018.1564565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
558 McGrath JS, Honrado C, Moore JH, Adair SJ, Varhue WB, Salahi A, Farmehini V, Goudreau BJ, Nagdas S, Blais EM, Bauer TW, Swami NS. Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry. Anal Chim Acta 2020;1101:90-8. [PMID: 32029124 DOI: 10.1016/j.aca.2019.12.033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
559 Yan L, Raj P, Yao W, Ying H. Glucose Metabolism in Pancreatic Cancer. Cancers (Basel) 2019;11:E1460. [PMID: 31569510 DOI: 10.3390/cancers11101460] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
560 Froeling FEM, Casolino R, Pea A, Biankin AV, Chang DK. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. J Clin Med 2021;10:E149. [PMID: 33406790 DOI: 10.3390/jcm10010149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
561 Kettle JG, Bagal SK, Bickerton S, Bodnarchuk MS, Breed J, Carbajo RJ, Cassar DJ, Chakraborty A, Cosulich S, Cumming I, Davies M, Eatherton A, Evans L, Feron L, Fillery S, Gleave ES, Goldberg FW, Harlfinger S, Hanson L, Howard M, Howells R, Jackson A, Kemmitt P, Kingston JK, Lamont S, Lewis HJ, Li S, Liu L, Ogg D, Phillips C, Polanski R, Robb G, Robinson D, Ross S, Smith JM, Tonge M, Whiteley R, Yang J, Zhang L, Zhao X. Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS G12C. J Med Chem 2020;63:4468-83. [DOI: 10.1021/acs.jmedchem.9b01720] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
562 Tanaka HY, Kano MR. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment. Cancer Sci 2018;109:2085-92. [PMID: 29737600 DOI: 10.1111/cas.13630] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
563 Hennig A, Wolf L, Jahnke B, Polster H, Seidlitz T, Werner K, Aust DE, Hampe J, Distler M, Weitz J, Stange DE, Welsch T. CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids. Stem Cells Int 2019;2019:1024614. [PMID: 31191661 DOI: 10.1155/2019/1024614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
564 Lee KE, Spata M, Bayne LJ, Buza EL, Durham AC, Allman D, Vonderheide RH, Simon MC. Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov 2016;6:256-69. [PMID: 26715642 DOI: 10.1158/2159-8290.CD-15-0822] [Cited by in Crossref: 104] [Cited by in F6Publishing: 70] [Article Influence: 17.3] [Reference Citation Analysis]
565 Maurel J, Sánchez-Cabús S, Laquente B, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Díaz-Beveridge R, Martín-Richard M, Rodriguez J, Sabater L, Conill C, Cambray M, Reig A, Ayuso JR, Valls C, Ferrández A, Bombí JA, Ginés A, García-Albéniz X, Fernández-Cruz L. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). Cancer Chemother Pharmacol 2018;82:935-43. [PMID: 30225601 DOI: 10.1007/s00280-018-3682-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
566 Moreira L, Bakir B, Chatterji P, Dantes Z, Reichert M, Rustgi AK. Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer. Cell Mol Gastroenterol Hepatol 2018;5:289-98. [PMID: 29541683 DOI: 10.1016/j.jcmgh.2017.12.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
567 [DOI: 10.1101/2021.01.13.426413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
568 Mukherjee I, Powell B, Parianos M, Downs D, Ross SB. Available technologies and clinical applications of targeted chemotherapy in pancreatic cancer. Cancer Genet 2016;209:582-91. [PMID: 27613576 DOI: 10.1016/j.cancergen.2016.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
569 Martinelli P, Madriles F, Cañamero M, Pau EC, Pozo ND, Guerra C, Real FX. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice. Gut 2016;65:476-86. [PMID: 25596178 DOI: 10.1136/gutjnl-2014-308042] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
570 Zinovyeva MV, Kostina MB, Chernov IP, Kondratyeva LG, Sverdlov ED. KLF5, a new player and new target in the permanently changing set of pancreatic cancer molecular drivers. Russ J Bioorg Chem 2016;42:606-11. [DOI: 10.1134/s1068162016060157] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
571 Sadozai H, Acharjee A, Gruber T, Gloor B, Karamitopoulou E. Pancreatic Cancers with High Grade Tumor Budding Exhibit Hallmarks of Diminished Anti-Tumor Immunity. Cancers (Basel) 2021;13:1090. [PMID: 33806316 DOI: 10.3390/cancers13051090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
572 Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol 2014;11:065002. [PMID: 25427073 DOI: 10.1088/1478-3975/11/6/065002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
573 Grzadkowski MR, Holly HD, Somers J, Demir E. Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes. BMC Bioinformatics 2021;22:233. [PMID: 33957863 DOI: 10.1186/s12859-021-04147-y] [Reference Citation Analysis]
574 Zheng-Lin B, O'Reilly EM. Pancreatic ductal adenocarcinoma in the era of precision medicine. Semin Oncol 2021:S0093-7754(21)00005-1. [PMID: 33637355 DOI: 10.1053/j.seminoncol.2021.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
575 Jentzsch V, Davis JAA, Djamgoz MBA. Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management. Cancers (Basel) 2020;12:E3096. [PMID: 33114159 DOI: 10.3390/cancers12113096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
576 Ciliberto D, Staropoli N, Chiellino S, Botta C, Tassone P, Tagliaferri P. Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. Pancreatology 2016;16:249-58. [PMID: 26852170 DOI: 10.1016/j.pan.2016.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
577 Wang J, Dumartin L, Mafficini A, Ulug P, Sangaralingam A, Alamiry NA, Radon TP, Salvia R, Lawlor RT, Lemoine NR, Scarpa A, Chelala C, Crnogorac-Jurcevic T. Splice variants as novel targets in pancreatic ductal adenocarcinoma. Sci Rep 2017;7:2980. [PMID: 28592875 DOI: 10.1038/s41598-017-03354-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
578 Felix TF, Lopez Lapa RM, de Carvalho M, Bertoni N, Tokar T, Oliveira RA, M Rodrigues MA, Hasimoto CN, Oliveira WK, Pelafsky L, Spadella CT, Llanos JC, F Silva G, Lam WL, Rogatto SR, Amorim LS, Drigo SA, Carvalho RF, Reis PP. MicroRNA modulated networks of adaptive and innate immune response in pancreatic ductal adenocarcinoma. PLoS One 2019;14:e0217421. [PMID: 31150430 DOI: 10.1371/journal.pone.0217421] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
579 Jeon CY, Pandol SJ, Wu B, Cook-Wiens G, Gottlieb RA, Merz CN, Goodman MT. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. PLoS One. 2015;10:e0121783. [PMID: 25830309 DOI: 10.1371/journal.pone.0121783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
580 Chen W, Huang F, Zhuang Y, Tang J, Zhuang X, Cheng W, Gu Z, Zhang S. Silencing of GATA6 Suppresses SW1990 Pancreatic Cancer Cell Growth In Vitro and Up-Regulates Reactive Oxygen Species. Dig Dis Sci 2013;58:2518-27. [DOI: 10.1007/s10620-013-2752-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
581 Pelosi E, Castelli G, Testa U. Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines. 2017;5. [PMID: 29156578 DOI: 10.3390/biomedicines5040065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
582 Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 2017;542:362-6. [PMID: 28178232 DOI: 10.1038/nature21064] [Cited by in Crossref: 68] [Cited by in F6Publishing: 52] [Article Influence: 17.0] [Reference Citation Analysis]
583 Kuo KK, Hsiao PJ, Chang WT, Chuang SC, Yang YH, Wuputra K, Ku CC, Pan JB, Li CP, Kato K, Liu CJ, Wu DC, Yokoyama KK. Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer. Cancers (Basel) 2021;13:3920. [PMID: 34359820 DOI: 10.3390/cancers13153920] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
584 Kaissis G, Ziegelmayer S, Lohöfer F, Steiger K, Algül H, Muckenhuber A, Yen HY, Rummeny E, Friess H, Schmid R, Weichert W, Siveke JT, Braren R. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy. PLoS One 2019;14:e0218642. [PMID: 31577805 DOI: 10.1371/journal.pone.0218642] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
585 Luley KB, Biedermann SB, Künstner A, Busch H, Franzenburg S, Schrader J, Grabowski P, Wellner UF, Keck T, Brabant G, Schmid SM, Lehnert H, Ungefroren H. A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1. Cancers (Basel) 2020;12:E691. [PMID: 32183367 DOI: 10.3390/cancers12030691] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
586 Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials 2016;93:71-82. [PMID: 27082874 DOI: 10.1016/j.biomaterials.2016.03.044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
587 Ungefroren H, Kumarasinghe A, Musfeldt M, Fiedler C, Lehnert H, Marquardt JU. RAC1B Induces SMAD7 via USP26 to Suppress TGFβ1-Dependent Cell Migration in Mesenchymal-Subtype Carcinoma Cells. Cancers (Basel) 2020;12:E1545. [PMID: 32545415 DOI: 10.3390/cancers12061545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
588 Khalil DN, O'Reilly EM. Classification of Pancreatic Cancer: Ready for Practical Application? Clin Cancer Res 2018;24:4355-6. [PMID: 29752276 DOI: 10.1158/1078-0432.CCR-18-1113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
589 Birnbaum DJ, Finetti P, Birnbaum D, Mamessier E, Bertucci F. XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. J Clin Med 2019;8:E596. [PMID: 31052304 DOI: 10.3390/jcm8050596] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
590 Liu P, Yang H, Zhang J, Peng X, Lu Z, Tong W, Chen J. The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma. Sci Rep 2017;7:5186. [PMID: 28701723 DOI: 10.1038/s41598-017-05274-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
591 Abou Khouzam R, Rao SP, Venkatesh GH, Zeinelabdin NA, Buart S, Meylan M, Nimmakayalu M, Terry S, Chouaib S. An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment. Front Immunol 2021;12:680435. [PMID: 34093582 DOI: 10.3389/fimmu.2021.680435] [Reference Citation Analysis]
592 Haider S, Wang J, Nagano A, Desai A, Arumugam P, Dumartin L, Fitzgibbon J, Hagemann T, Marshall JF, Kocher HM, Crnogorac-Jurcevic T, Scarpa A, Lemoine NR, Chelala C. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med 2014;6:105. [PMID: 25587357 DOI: 10.1186/s13073-014-0105-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
593 Gendoo DMA, Denroche RE, Zhang A, Radulovich N, Jang GH, Lemire M, Fischer S, Chadwick D, Lungu IM, Ibrahimov E, Cao PJ, Stein LD, Wilson JM, Bartlett JMS, Tsao MS, Dhani N, Hedley D, Gallinger S, Haibe-Kains B. Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. PLoS Comput Biol 2019;15:e1006596. [PMID: 30629588 DOI: 10.1371/journal.pcbi.1006596] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
594 Bachet JB, Maréchal R, Demetter P, Bonnetain F, Cros J, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Vaillant JC, André T, Closset J, Salmon I, Emile JF, Van Laethem JL. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Eur J Cancer 2013;49:2643-53. [PMID: 23726265 DOI: 10.1016/j.ejca.2013.04.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
595 Casolino R, Braconi C, Malleo G, Paiella S, Bassi C, Milella M, Dreyer SB, Froeling FEM, Chang DK, Biankin AV, Golan T. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol 2021;32:183-96. [PMID: 33248227 DOI: 10.1016/j.annonc.2020.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
596 Yuan S, Natesan R, Sanchez-Rivera FJ, Li J, Bhanu NV, Yamazoe T, Lin JH, Merrell AJ, Sela Y, Thomas SK, Jiang Y, Plesset JB, Miller EM, Shi J, Garcia BA, Lowe SW, Asangani IA, Stanger BZ. Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression. Cancer Discov 2020;10:854-71. [PMID: 32188706 DOI: 10.1158/2159-8290.CD-19-1299] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 16.0] [Reference Citation Analysis]
597 Bhutani MS, Cazacu IM, Roy-Chowdhuri S, Maitra A, Pishvaian MJ. Upfront molecular profiling of pancreatic cancer patients - An idea whose time has come. Pancreatology 2020;20:391-3. [PMID: 32192904 DOI: 10.1016/j.pan.2020.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
598 Sandhu V, Labori KJ, Borgida A, Lungu I, Bartlett J, Hafezi-bakhtiari S, Denroche RE, Jang GH, Pasternack D, Mbaabali F, Watson M, Wilson J, Kure EH, Gallinger S, Haibe-kains B. Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma. JCO Clinical Cancer Informatics 2019. [DOI: 10.1200/cci.18.00102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
599 Balic A, Dorado J, Alonso-Gómez M, Heeschen C. Stem cells as the root of pancreatic ductal adenocarcinoma. Exp Cell Res 2012;318:691-704. [PMID: 22119145 DOI: 10.1016/j.yexcr.2011.11.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
600 Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012;122:639-53. [PMID: 22232209 DOI: 10.1172/JCI59227] [Cited by in Crossref: 421] [Cited by in F6Publishing: 282] [Article Influence: 46.8] [Reference Citation Analysis]
601 Vasudevan P, Murugesan T. Cancer Subtype Discovery Using Prognosis-Enhanced Neural Network Classifier in Multigenomic Data. Technol Cancer Res Treat 2018;17:1533033818790509. [PMID: 30092720 DOI: 10.1177/1533033818790509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
602 Oldfield LE, Connor AA, Gallinger S. Molecular Events in the Natural History of Pancreatic Cancer. Trends Cancer 2017;3:336-46. [PMID: 28718411 DOI: 10.1016/j.trecan.2017.04.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
603 Chandana S, Babiker HM, Mahadevan D. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs 2018;28:161-77. [DOI: 10.1080/13543784.2019.1557145] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
604 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
605 Ma J, Hobbs BP, Stingo FC. Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 2018;27:2093-113. [PMID: 27807177 DOI: 10.1177/0962280216675373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
606 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
607 De Blasio A, Vento R, Di Fiore R. Mcl-1 targeting could be an intriguing perspective to cure cancer. J Cell Physiol 2018;233:8482-98. [PMID: 29797573 DOI: 10.1002/jcp.26786] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
608 Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, Saur D, Schneider G. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia 2011;13:1026-34. [PMID: 22131878 DOI: 10.1593/neo.111016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
609 Zhao B, Dierichs L, Gu JN, Trajkovic-Arsic M, Axel Hilger R, Savvatakis K, Vega-Rubin-de-Celis S, Liffers ST, Peña-Llopis S, Behrens D, Hahn S, Siveke JT, Lueong SS. TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Cell Death Discov 2020;6:12. [PMID: 32194992 DOI: 10.1038/s41420-020-0246-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
610 Heinzman Z, Schmidt C, Sliwinski MK, Goonesekere NCW. The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer. Pharmaceuticals (Basel) 2021;14:209. [PMID: 33802396 DOI: 10.3390/ph14030209] [Reference Citation Analysis]
611 Kelber JA, Reno T, Kaushal S, Metildi C, Wright T, Stoletov K, Weems JM, Park FD, Mose E, Wang Y, Hoffman RM, Lowy AM, Bouvet M, Klemke RL. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res 2012;72:2554-64. [PMID: 22589274 DOI: 10.1158/0008-5472.CAN-11-3552] [Cited by in Crossref: 73] [Cited by in F6Publishing: 47] [Article Influence: 8.1] [Reference Citation Analysis]
612 Mohammad J, Dhillon H, Chikara S, Mamidi S, Sreedasyam A, Chittem K, Orr M, Wilkinson JC, Reindl KM. Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models. Oncotarget 2018;9:10457-69. [PMID: 29535819 DOI: 10.18632/oncotarget.23623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
613 Fong CYK, Burke E, Cunningham D, Starling N. Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. Gastroenterol Res Pract 2019;2019:7135437. [PMID: 31582971 DOI: 10.1155/2019/7135437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
614 Bianconi D, Herac M, Spies D, Kieler M, Brettner R, Unseld M, Fürnkranz K, Famler B, Schmeidl M, Minichsdorfer C, Zielinski C, Heller G, Prager GW. SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment. Transl Oncol 2019;12:15-23. [PMID: 30245304 DOI: 10.1016/j.tranon.2018.08.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
615 Ding LY, Hou YC, Kuo IY, Hsu TY, Tsai TC, Chang HW, Hsu WY, Tsao CC, Tian CC, Wang PS, Wang HC, Lee CT, Wang YC, Lin SH, Hughes MW, Chuang WJ, Lu PJ, Shan YS, Huang PH. Epigenetic silencing of AATK in acinar to ductal metaplasia in murine model of pancreatic cancer. Clin Epigenetics 2020;12:87. [PMID: 32552862 DOI: 10.1186/s13148-020-00878-6] [Reference Citation Analysis]
616 Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochim Biophys Acta Rev Cancer 2021;1875:188461. [PMID: 33157162 DOI: 10.1016/j.bbcan.2020.188461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
617 Ritchie C, Mack A, Harper L, Alfadhli A, Stork PJS, Nan X, Barklis E. Analysis of K-Ras Interactions by Biotin Ligase Tagging. Cancer Genomics Proteomics 2017;14:225-39. [PMID: 28647697 DOI: 10.21873/cgp.20034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
618 Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013;32:1616-25. [PMID: 22614017 DOI: 10.1038/onc.2012.193] [Cited by in Crossref: 543] [Cited by in F6Publishing: 541] [Article Influence: 60.3] [Reference Citation Analysis]
619 Ardito CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 2012;22:304-317. [PMID: 22975374 DOI: 10.1016/j.ccr.2012.07.024] [Cited by in Crossref: 326] [Cited by in F6Publishing: 295] [Article Influence: 36.2] [Reference Citation Analysis]
620 Chung S, Vail P, Witkiewicz AK, Knudsen ES. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer. Clin Cancer Res 2019;25:2290-304. [PMID: 30538111 DOI: 10.1158/1078-0432.CCR-18-1620] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
621 Handler J, Cullis J, Avanzi A, Vucic EA, Bar-Sagi D. Pre-neoplastic pancreas cells enter a partially mesenchymal state following transient TGF-β exposure. Oncogene 2018;37:4334-42. [PMID: 29713060 DOI: 10.1038/s41388-018-0264-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
622 Kruger S, Haas M, Ormanns S, Bächmann S, Siveke JT, Kirchner T, Heinemann V, Boeck S. Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. World J Gastroenterol 2014;20:10769-77. [PMID: 25152580 DOI: 10.3748/wjg.v20.i31.10769] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
623 Hwang CI, Boj SF, Clevers H, Tuveson DA. Preclinical models of pancreatic ductal adenocarcinoma. J Pathol. 2016;238:197-204. [PMID: 26419819 DOI: 10.1002/path.4651] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
624 Wei T, Zhang J, Li J, Chen Q, Zhi X, Tao W, Ma J, Yang J, Lou Y, Ma T, Li X, Zhang Q, Chen W, Que R, Gao S, Bai X, Liang T. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Mol Oncol 2020;14:1966-77. [PMID: 32593194 DOI: 10.1002/1878-0261.12757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
625 Juiz NA, Iovanna J, Dusetti N. Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome. Front Oncol 2019;9:246. [PMID: 31024848 DOI: 10.3389/fonc.2019.00246] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
626 Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012;38:843-53. [PMID: 22226241 DOI: 10.1016/j.ctrv.2011.12.004] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 9.0] [Reference Citation Analysis]
627 Gutiérrez ML, Corchete L, Teodosio C, Sarasquete ME, del Mar Abad M, Iglesias M, Esteban C, Sayagues JM, Orfao A, Muñoz-Bellvis L. Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas. Oncotarget 2015;6:19070-86. [PMID: 26053098 DOI: 10.18632/oncotarget.4233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
628 Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills GB, O'Reilly EM, Knudsen ES. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. Cell Rep. 2016;16:2017-2031. [PMID: 27498862 DOI: 10.1016/j.celrep.2016.07.023] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 13.8] [Reference Citation Analysis]
629 Baslan T, Hicks J. Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat Rev Cancer 2017;17:557-69. [DOI: 10.1038/nrc.2017.58] [Cited by in Crossref: 126] [Cited by in F6Publishing: 100] [Article Influence: 31.5] [Reference Citation Analysis]
630 Sivapalan L, Kocher HM, Ross-Adams H, Chelala C. Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application. Pancreatology. 2021;21:363-378. [PMID: 33451936 DOI: 10.1016/j.pan.2020.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
631 Lundgren S, Hau SO, Elebro J, Heby M, Karnevi E, Nodin B, Eberhard J, Holm K, Staaf J, Jönsson GB, Jirström K. Mutational Landscape in Resected Periampullary Adenocarcinoma: Relationship With Morphology and Clinical Outcome. JCO Precis Oncol 2019;3:PO. [PMID: 32914025 DOI: 10.1200/PO.18.00323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
632 Romano O, Miccio A. GATA factor transcriptional activity: Insights from genome-wide binding profiles. IUBMB Life 2020;72:10-26. [PMID: 31574210 DOI: 10.1002/iub.2169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
633 Nussinov R, Muratcioglu S, Tsai C, Jang H, Gursoy A, Keskin O. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target? Expert Opinion on Therapeutic Targets 2016;20:831-42. [DOI: 10.1517/14728222.2016.1135131] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
634 Perera RM, Bardeesy N. Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. Cancer Discov 2015;5:1247-61. [PMID: 26534901 DOI: 10.1158/2159-8290.CD-15-0671] [Cited by in Crossref: 116] [Cited by in F6Publishing: 62] [Article Influence: 19.3] [Reference Citation Analysis]
635 Mathew E, Zhang Y, Holtz AM, Kane KT, Song JY, Allen BL, Pasca di Magliano M. Dosage-dependent regulation of pancreatic cancer growth and angiogenesis by hedgehog signaling. Cell Rep 2014;9:484-94. [PMID: 25310976 DOI: 10.1016/j.celrep.2014.09.010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
636 Cantini L, Medico E, Fortunato S, Caselle M. Detection of gene communities in multi-networks reveals cancer drivers. Sci Rep 2015;5:17386. [PMID: 26639632 DOI: 10.1038/srep17386] [Cited by in Crossref: 57] [Cited by in F6Publishing: 27] [Article Influence: 9.5] [Reference Citation Analysis]
637 Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73:1128-1141. [PMID: 23221383 DOI: 10.1158/0008-5472.can-12-2731] [Cited by in Crossref: 541] [Cited by in F6Publishing: 367] [Article Influence: 60.1] [Reference Citation Analysis]
638 Lecuelle J, Aarnink A, Tharin Z, Truntzer C, Ghiringhelli F. Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma. Cancers (Basel) 2021;13:1851. [PMID: 33924443 DOI: 10.3390/cancers13081851] [Reference Citation Analysis]
639 Kaur K, Chang HH, Topchyan P, Cook JM, Barkhordarian A, Eibl G, Jewett A. Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice. Front Immunol. 2018;9:1229. [PMID: 29977235 DOI: 10.3389/fimmu.2018.01229] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
640 Fokas E, O’Neill E, Gordon-Weeks A, Mukherjee S, McKenna WG, Muschel RJ. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Biochim Biophys Acta. 2015;1855:61-82. [PMID: 25489989 DOI: 10.1016/j.bbcan.2014.12.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
641 Søreide K, Sund M. Epidemiological-molecular evidence of metabolic reprogramming on proliferation, autophagy and cell signaling in pancreas cancer. Cancer Lett 2015;356:281-8. [PMID: 24704294 DOI: 10.1016/j.canlet.2014.03.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
642 Lai ZW, Bolm L, Fuellgraf H, Biniossek ML, Makowiec F, Hopt UT, Werner M, Keck T, Bausch D, Sorio C, Scarpa A, Schilling O, Bronsert P, Wellner UF. Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses. BMC Cancer 2016;16:195. [PMID: 26951071 DOI: 10.1186/s12885-016-2193-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
643 Real FX, de Andrés MP. Mutant Kras Dosage and Chromothripsis: The Right Ingredients for a Pancreatic Cancer Catastrophe. Trends Cancer 2018;4:399-401. [PMID: 29860982 DOI: 10.1016/j.trecan.2018.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
644 Miyabayashi K, Nakagawa H, Koike K. Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives. Front Oncol 2021;11:682872. [PMID: 34249730 DOI: 10.3389/fonc.2021.682872] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
645 De Sousa E Melo F, Vermeulen L, Fessler E, Medema JP. Cancer heterogeneity--a multifaceted view. EMBO Rep. 2013;14:686-695. [PMID: 23846313 DOI: 10.1038/embor.2013.92] [Cited by in Crossref: 140] [Cited by in F6Publishing: 109] [Article Influence: 17.5] [Reference Citation Analysis]
646 Knudsen ES, Kumarasamy V, Ruiz A, Sivinski J, Chung S, Grant A, Vail P, Chauhan SS, Jie T, Riall TS, Witkiewicz AK. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Oncogene 2019;38:3355-70. [PMID: 30696953 DOI: 10.1038/s41388-018-0650-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
647 Marks DL, Olson RL, Urrutia R, Billadeau DD, Roy N, Calin GA, Fabbri M, Koutsioumpa M, Iliopoulos D, Ordog T, Huebert R, Sarmento O, Bamidele AO, Faubion W, Lomberk GL, Siveke J, Ahuja N, Iovanna J, Hlady RA, Robertson K, Kisiel J, Pin CL, Fernandez-Zapico ME. Epigenetics of gastrointestinal diseases: notes from a workshop. Epigenetics 2018;13:449-57. [PMID: 30056798 DOI: 10.1080/15592294.2018.1464351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
648 Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O'Kane GM, Albaba H, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, Ghai S, Lemire M, Holter S, Connor AA, Moffitt RA, Yeh JJ, Timms L, Krzyzanowski PM, Dhani N, Hedley D, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res. 2018;24:1344-1354. [PMID: 29288237 DOI: 10.1158/1078-0432.ccr-17-2994] [Cited by in Crossref: 192] [Cited by in F6Publishing: 83] [Article Influence: 48.0] [Reference Citation Analysis]
649 Follia L, Ferrero G, Mandili G, Beccuti M, Giordano D, Spadi R, Satolli MA, Evangelista A, Katayama H, Hong W, Momin AA, Capello M, Hanash SM, Novelli F, Cordero F. Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers. Front Oncol. 2019;9:115. [PMID: 30873387 DOI: 10.3389/fonc.2019.00115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
650 Buckley D, Duke G, Heuer TS, O'farrell M, Wagman AS, Mcculloch W, Kemble G. Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target. Pharmacology & Therapeutics 2017;177:23-31. [DOI: 10.1016/j.pharmthera.2017.02.021] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 16.0] [Reference Citation Analysis]
651 Humphrey ES, Su SP, Nagrial AM, Hochgräfe F, Pajic M, Lehrbach GM, Parton RG, Yap AS, Horvath LG, Chang DK, Biankin AV, Wu J, Daly RJ. Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Mol Cell Proteomics 2016;15:2671-85. [PMID: 27259358 DOI: 10.1074/mcp.M116.058313] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
652 Lamarca A, Feliu J. Pancreatic biomarkers: could they be the answer? World J Gastroenterol 2014;20:7819-29. [PMID: 24976720 DOI: 10.3748/wjg.v20.i24.7819] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
653 Li H, Peng C, Zhu C, Nie S, Qian X, Shi Z, Shi M, Liang Y, Ding X, Zhang S, Zhang B, Li X, Xu G, Lv Y, Wang L, Friess H, Kong B, Zou X, Shen S. Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent manner. Clin Epigenetics 2021;13:18. [PMID: 33499904 DOI: 10.1186/s13148-021-01016-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
654 Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Med 2017;15:170. [PMID: 28927421 DOI: 10.1186/s12916-017-0936-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
655 Lee Y, Lee H, Park H, Kim JW, Hwang JH, Kim J, Yoon YS, Han HS, Kim H. Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas. Oncotarget 2017;8:76699-711. [PMID: 29100342 DOI: 10.18632/oncotarget.20815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
656 Venkat S, Alahmari AA, Feigin ME. Drivers of Gene Expression Dysregulation in Pancreatic Cancer. Trends Cancer 2021;7:594-605. [PMID: 33618999 DOI: 10.1016/j.trecan.2021.01.008] [Cited by in Crossref: 1] [